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ABSTRACT 
 
 Mammalian Orthoreovirus (MRV), a double-stranded RNA virus, is a potent 
oncolytic virus, which specifically replicates in tumor cells and consequently kills them. 
Hypoxia, a condition of low oxygen, is a characteristic feature of most solid tumors and 
develops due to tumor cells outgrowing their blood supply. Hypoxic cell survival is 
driven by the transcriptional activity of hypoxia inducible factor-1 (HIF-1). We examined 
the ability of MRV to infect hypoxic prostate tumor cells and found that not only did it 
successfully translate proteins and replicate in hypoxic prostate tumor cells, it also 
induced apoptosis. In addition, MRV induced downregulation of the HIF-1α protein, 
through a ubiquitin-dependent proteasome-mediated pathway, required the PAS domain 
of HIF-1α and was rescued by knockdown of the Receptor for Activated C Kinase 1 
(RACK1).  
 We investigated the direct involvement of any MRV proteins in the 
downregulation of HIF-1α and found that proteins µ1 and µ2 were able to downregulate 
HIF-1α independently. Strain specific difference (specifically the aa at 208th position of 
the protein) was found to affect the ability of µ2 to induce downregulation of HIF-1α; the 
T1L and T3DC causing more downregulation than the T3DF MRV strains. The region of 
µ2 containing aa 188-380 and the φ domain of µ1 were determined to be needed for HIF-
1α downregulation.  
 The dependence of Prostate Cancer (PCa) on androgens for growth and survival is 
exploited by the hormone therapy, where androgen deprivation is used as a viable 
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therapy. Although initially successfully, this androgen dependent PCa progresses to 
androgen independent PCa, in which hypoxia has been proven to play a vital role. We 
examined the effect of MRV infection on hypoxic androgen dependent LNCaP cells and 
found that MRV induced apoptosis in hypoxic and normoxic LNCaP cells and also 
inhibited Akt activity and downregulated Prostate Specific Antigen (PSA). MRV 
infection also caused the downregulation of Androgen receptor (AR) activity and protein, 
primarily by translation inhibition. 
 Overall, our work highlights the potential use of MRV at various stages of PCa 
and lays important groundwork for the design of clinical trials based on MRV targeting 
hypoxic PCa cells at all stages. 
 1  
CHAPTER 1. GENERAL INTRODUCTION 
 
 Viruses capable of selectively killing cancer cells are termed oncolytic viruses. 
They are either naturally occurring or genetically modified. Mammalian Orthoreovirus 
(MRV) is a naturally occurring oncolytic virus [1]. It is a member of family Reoviridae, 
and is a non-enveloped double stranded RNA virus.  The 10-segmented genome encodes 
for 8 structural and 4 non-structural proteins, and is surrounded by two concentric 
icosahedral capsids. MRV is a benign virus, unable to cause major diseases in humans. 
This makes it safe to be used as an oncolytic virus. MRV’s oncolytic potential has been 
substantiated in numerous cancer cell lines and immunodeficient mice xenograft models 
and phase I/II/III human clinical trials [2-14]. The mode of cell death in most of these 
studies was determined to be apoptosis, which is the same as the known mechanism of 
MRV cytotoxicity [15-17]. An activated Ras pathway in transformed and cancer cells 
was attributed to be responsible for the specificity of MRV infectivity [18, 19], although 
this hypothesis has been challenged [20].   
Low tissue oxygen levels, known as hypoxia, are a common feature of solid 
tumors. As a tumor rapidly grows, the blood supply often becomes inadequate due to a 
leaky or dysfunctional vasculature, and causes poor oxygen delivery thereby creating a 
hypoxic microenvironment. Hypoxia presence is highly correlated with disease 
progression and mortality in cancer [21] and resistance to radiation therapy and 
chemotherapy drugs [22, 23]. Cells adapt to this otherwise fatal condition through the 
upregulation of genes encoding proteins that promote apoptosis resistance, metastasis and 
angiogenesis [24]. The hypoxic cell is controlled by the transcription factor, hypoxia 
 2  
inducible factor 1 (HIF-1). HIF-1 is a heterodimer of two proteins, HIF-1α and HIF-1β. 
When HIF-1α and HIF-1β are present, they form a dimer, translocate to the nucleus and 
bind to canonical DNA sequences termed hypoxia response elements (HREs) in the 
promoter or enhancer regions of target genes [25]. The formation of HIF-1 is dependent 
on the availability of HIF-1α, which is tightly regulated post-translationally via oxygen-
dependent and -independent degradation pathways [26].  
Prostate cancer (PCa) is the second leading cause of cancer death in men in the 
United States [27]. PCa is dependent on androgens for growth and androgen signaling, in 
turn, is mediated by the androgen receptor (AR), a ligand-activated transcription factor 
[28]. After binding to androgen, the AR translocates into the nucleus and binds to specific 
sequences (androgen response elements or ARE) in the promoter or enhancer regions of 
target genes, thereby promoting their transcription. Therapies, such as surgical removal 
and radiotherapy, have undesired side effects namely impotency and urinary incontinence 
[29]. Hormone therapy, involving surgical or chemical deprivation of androgen, is 
another viable treatment option for PCa patients. However, most prostate tumors advance 
to androgen resistance within one to three years of therapy and recommence growth.  
This castrate resistant PCa (CRPC) is treated with a few approved drugs such as 
docetaxel, but the disease rapidly develops drug resistance.  
Hypoxia and hypoxia regulated proteins in PCa, at both earlier and later stages, 
have been linked to disease advancement, poor prognosis, low survival rate and relapse 
[30, 31]. Hypoxia causes amplified AR activity and sensitivity leading to PCa growth 
under extremely low androgen concentrations [32]. The process of castration leads to 
severe reduction in blood flow to the prostate tumor and activated hypoxic signaling [32]. 
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Bearing in mind that PCa profits from presence of hypoxia for persistence and metastasis, 
there is a critical necessity for the development of therapeutics directed at hypoxic PCa 
cells.   
Where few oncolytic viruses failed to replicate under hypoxic conditions [33, 34], 
MRV was found to successfully replicate under hypoxic conditions in different cancer 
cell lines, but have contradictory effect on HIF-1α. MRV infection was shown to cause 
diminished HIF-1α in hypoxic lung, colon and renal cancer cell lines [35], but in 
disagreement, caused its stabilization in glioblastoma cell line [36]. In our study, we 
investigated the effect of MRV infection in hypoxic PCa cell lines and found that MRV 
causes downregulation of HIF-1α. Following this discovery, we investigated the 
pathways and proteins involved in this downregulation, both in the host cell and MRV. 
Since progression of androgen dependent PCa to CRPC is a critical step in PCa 
progression, and is known to be heavily regulated by hypoxia, we examined the 
molecular effects of MRV infection on the key regulatory proteins in androgen dependent 
hypoxic and normoxic LNCaP cells. 
The results from our studies are presented in the following chapters and aims at 
augmenting the known effects of MRV on hypoxic microenvironment, and more 
specifically, aid in the designing of unique clinical trails and studies in hypoxic PCa 
targeting all its stages.  
Dissertation Organization 
This dissertation is presented as six chapters. Chapter 1 provides a general introduction 
and provides the rationale behind the research described in this thesis. Chapter 2 is the 
literature review of MRV and hypoxia, as relevant to this thesis. Chapter 3 consists of a 
 4  
manuscript, published in the journal Oncotarget, about the effect of MRV infection on 
HIF-1α downregulation and the pathways involved. Chapter 4 is about the MRV proteins 
which cause downregulation of HIF-1α, and is being prepared for submission in the 
journal Virology. Chapter 5 describes the work on the effect of MRV infection on key 
regulatory proteins of hypoxic and normoxic LNCaP cells, which has been submitted to 
the journal BMC Cancer. For the work presented in Chapter 4 and 5, PGS and CLM 
conceived and designed the study and PGS and TM performed the experiments. Chapter 
6 summarizes the results from the previous 3 chapters as General Conclusions. 
References can be found at the end of each chapter. 
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CHAPTER 2. LITERATURE REVIEW 
 
Introduction 
 Mammalian Orthoreovirus (MRV) is a double stranded RNA virus. Member of 
the Reoviridae family, it is non-enveloped, multilayered and has an icosahedral protein 
capsid. The genome is 23.5 Kilobases (Kb) and consists of 10 RNA segments, 3 large 
(L1, L2 and L3), 3 medium (M1, M2 and M3) and 4 small (S1, S2, S3 and S4). They 
encode for eight structural (λ1, λ2, λ3, µ1, µ2, σ1, σ2 and σ3) and four non-structural 
(µNS, µNSC, σ1s and σNS) proteins. The genome is surrounded two concentric 
icosahedral capsids (Fig 2.1). The innermost capsid, a self-contained transcriptome unit, 
is known as the core and comprises of λ1, λ3, µ1 and σ2. The core is surrounded by an 
outer capsid made of 4 proteins (λ2, µ2, σ1, σ3), which plays a role in virus entry. The 
name reovirus stands for respiratory enteric orphan virus. MRV infects all mammals 
including humans, and is generally non-pathogenic [1], although rare cases of reovirus 
encephalitis has been documented in children [2]. They are commonly isolated from 
mammalian feces, as well as from fresh and saltwater sources. Three MRV serotypes 
have been recognized based on neutralization and hemagglutination profiles, type 1 Lang 
(T1L), type 2 Jones (T2J), and type 3 Dearing (T3D), which differ primarily in their σ1 
sequence [3-5]. In addition, a serotype 3 variant, strain Abney (T3A) was isolated form 
an anal swab of a baby suffering from gastrointestinal illness [6, 7]. MRV is taken up by 
the M cells in the intestine [8] after oral inoculation in newborn mice and primary 
infection takes place in lymphoid tissue of Peyer’s patches before travelling to other 
secondary sites such as heart, brain and liver [9]. T1 spreads to the CNS hematogenously 
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and infects ependymal cells [10, 11], resulting in hydrocephalus [12]. On the other hand, 
T3 MRV spreads to the CNS and infects neurons [9-11] causing lethal encephalitis.  
 
Figure 2.1. Organization of virus particles. Image adapted from Chandran et al [13]. 
Upper row shows surface-shaded views of reovirus virion, intermediate subvirion particle 
(ISVP) and core. Lower row shows schematic cross-sectional views of a portion of each 
particle.  
 
MRV Life Cycle 
Entry of MRV in a host cell is mediated through binding of the primary receptor, 
junction adhesion molecule (JAM-A) and secondary receptor, sialic acid (SA) with an 
outer coat protein σ1[14, 15]. The attachment protein σ1 is encoded by the S1 gene, and 
is a trimeric molecule with a distinct head and tail morphology [16, 17]. The σ1 tail 
partially inserts into the virion, while the head projects away from the surface [17, 18].  
The N-terminal σ1 tail binds to sialic acid and the C-terminal σ1 head binds to JAM-A 
[14, 19, 20]. A low-affinity interaction with SA serves to fasten the virion to target cells 
and is followed by a high-affinity interaction with JAM-A [21]. However, SA binding is 
not a necessary prerequisite for JAM-A binding [14]. Binding to JAM-A is required for 
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establishing infection and dissemination via the bloodstream to secondary sites of 
infection in the host [22].  In the central nervous system (CNS) MRV (T1L) does not 
need JAM-A for binding [22]. A recent study reports that in the CNS, MRV uses Nogo 
receptor NgR1, a leucine-rich repeat protein expressed in the CNS, to infect neurons	  [23]. 
Following attachment MRV is taken up by clathrin-mediated endocytosis into the 
cell [24-26], and is followed by proteolytic cleavage of the outer capsid, producing 
several intermediate particles that allow for the release of MRV into the cytoplasm. One 
such particle is an Intermediate Sub-Virion Particle (ISVP) (Fig 2.1). The ISVP is highly 
infectious and has the previously shielded µ1 protein exposed due to the cleavage of σ3. 
Autolytic cleavage of µ1 divides it into myristoylated µ1N and µ1C and then further to δ 
and φ fragments [27-29].  The myristoylated µ1N inserts and creates holes in the 
endosomal membrane to release the viral core particles into the cytoplasm [20, 30].  
Once in the cytoplasm, primary transcription occurs within the core particle where 
positive stranded mRNA is produced within the core by the virus encoded λ3 RNA 
dependent RNA polymerase [31]. Cores lack µ1 and σ1 and are poorly infectious, 
suggesting that µ1 and σ1 is important for infection. M1-encoded protein µ2 has been 
shown to have RNA-binding, NTPase and RTPase activities and thus plays important 
role in viral mRNA synthesis [32-34].  This positive stranded mRNA is extruded through 
the viral turrets formed by λ2, [13] and is capped at the 5’ end before release into the 
cytoplasm [35] where it is believed to be translated  using cellular translation machinery. 
However, a recent study showed that active translation occurs within viral factories (VFs, 
see below) and that translational factors are compartmentalized within factories. They 
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also demonstrated that σNS associates with 43S preinitiation complexes at the factory 
margins, suggesting that σNS plays some role in translation [36].  
 
Figure 2.2. MRV life cycle Cell attachment occurs via σ1. Following attachment 
receptor-mediated endocytosis induces shedding of σ1 and σ3 and µ1c is cleaved by 
endocytic proteases disassociates endosome. Primary transcription occurs within the 
cores mRNA released. Primary translation of all 10 mRNA using host translation 
machinery occurs and then the viral proteins accumulate in VFs. Here new cores 
assemble and synthesis of minus-strand RNA takes place. Secondary transcription occurs 
within new cores. The outer capsids assemble and new virions are released.  
 
Once translation begins, nonstructural protein µNS binds to viral cores to make globular 
structures called viral factories (VFs) or inclusion bodies. VFs do not have a delimiting 
membrane and contains viral proteins, dsRNAs and also some cellular proteins [37]. The 
carboxyl-proximal domains (amino-acids 471-721) of µNS, including two predicted 
coiled-coil domains are necessary and sufficient for forming the viral factory-like matrix 
[38]. N-terminal regions of µNS recruit other viral proteins as well as intact viral core 
particles to viral factories [37, 39, 40]. Binding of µNS to core particles does not inhibit 
the transcription and capping activities of cores [41]. Another protein, µ2 that associates 
with the microtubule, binds µNS and helps transports these VFs for the construction of 
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large structures surrounding the nucleus [41, 42]. Occasional MRV strains form globular 
viral factories, while most strains form filamentous structures. The globular or 
filamentous morphology of viral factories was mapped to the MRV µ2 protein [43]. Viral 
assembly takes place within these VFs, where the eight nonstructural MRV proteins 
begin to assemble into cores. After core assembly the positive stranded mRNA enters the 
particle through the λ2 turret and the complementary negative sense mRNA is 
synthesized by λ3 to create the complete dsRNA genome [44, 45]. Following the core 
assembly, the outer capsid starts to assemble on the core and full infectious viral particle 
is produced [46]. The virus particle release is not well understood, and is thought to be 
facilitated by cell lysis and apoptosis. 
MRV Apoptosis 
MRV infection induces apoptosis in cell in vitro and in vivo. Studies of strain-
specific differences in the efficiency of apoptosis induction revealed important 
information about the mechanism used by MRV to induce apoptosis. MRV protein σ1 
encoded by gene S1 [47-49] and µ1 protein encoded by M2 was found to contribute to 
apoptosis induction efficiency by MRV [50, 51].  MRV created using reverse genetics 
with µ1 mutants was found to be less efficient in inducing apoptosis [50, 52]. Inhibiting 
endocytic proteases with ammonium chloride, blocks MRV induced apoptosis. ISVPs 
created in vitro can induce apoptosis but can be also blocked by ammonium chloride. 
This indicates that viral disassembly and endosomal events are required for apoptosis 
[53]. In vitro MRV RNA and protein synthesis is not required for apoptosis induction, 
suggesting that the infecting capsids are sufficient for apoptosis [51, 53]. Blocking virus 
binding to SA abolishes the capacity of T3SA+ to induce apoptosis [47]. However SA 
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binding is not sufficient. σ1 binding to JAM-A blockage by using antibodies to either 
JAM-A or σ1 also reduced the capacity of MRV to induce apoptosis [14, 49].  Hence, σ1 
attachment to both SA and JAM-A is required for MRV induced efficient apoptosis.  
MRV induced apoptosis activates a critical component of the signaling pathways, 
the nuclear factor – κB (NF-κB) [54]. NF-κB is a family of structurally related 
transcription factors, which play critical role in cellular survival and growth. Inhibitor of 
κB (IκB) family of proteins inhibits its activation. IκB is ubiquitinated and targeted to the 
proteasome by site-specific phosphorylation, and this allows for NF-κB activation. IκBα 
levels were found to be significantly reduced by 4 h post infection, indicating that it is the 
primary target of MRV [55]. Using siRNAs it was shown that IκB kinase α (IKKα), but 
not IKKβ is required for NF-κB activation. In cells lacking IKKβ regulatory subunit NF-
κB essential modifier (NEMO)/IKKγ MRV was unable to activate NF-κB and cause 
apoptosis [55]. NF-κB is activated my MRV infection 2-4 h post infection in cells and 
reaches maximum activation by 8-10 h [54]. Cells lacking either p50 or p65, which are 
part of the complexes activated during MRV infection, are unable to activate NF-κB 
under MRV infection, suggesting the requirement of these subunits [54].  The exact 
mechanism of NF-κB activation followed by MRV is not well understood. The NF-κB 
activation by MRV is also dependent upon SA [47] and JAM-A [56] attachment. 
Disassembly of the virus, but not subsequent replication steps is also required for NF-κB 
activation [53]. Another recent study found that the Immunoreceptor tyrosine-based 
activation motifs (ITAMs) in µ2 of T3D, recruits the ITAM signaling intermediate Syk to 
VFs and activates NF-κB and IFN-β [57].   
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Figure 2.3. Programmed cell death by activation of the intrinsic and extrinsic 
apoptotic pathways by MRV infection. The extrinsic pathway is activated during MRV 
infection release of TRAIL, upregulation of cell surface DR 4 and DR5, and activation of 
caspase-8. Activated caspase-8 cleaves Bid to generate t-Bid, which is then recruited to 
the outer mitochondrial membrane, where it activates the proapoptotic Bcl-2 proteins Bax 
and Bak, resulting in the subsequent release of cytochrome c. This induces 
oligomerization of Apaf-1, assembly of the apoptosome, and activation of caspase-9. 
MRV protein µ1 has been reported to cause release of cytochrome c independent of Bax 
and Bak. Release of smac/DIABLO inhibits the action of IAP, which can inhibit effector 
caspases. Both caspases 8 and 9 subsequently activate caspase 3/7 for apoptosis. 
 
MRV induced apoptosis requires both, the extrinsic death receptor pathway and 
mitochondria damage related, intrinsic pathway (Fig. 2.3). Activation of the extrinsic 
pathway is mediated by Tumor necrosis factor (TNF)-related apoptosis-inducing ligand 
(TRAIL) and its cell surface death receptors (DRs) DR4 and DR5 [58]. These then 
induce DR oligomerization and the close association of their cytoplasmic death domains 
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(DDs). The cytosolic adapter molecule Fas-Associated protein with Death Domain 
(FADD) and the pro-caspase 8 and 10 are then recruited to the receptor to form the death-
inducing signaling complex (DISC), followed by pro-caspase cleavage. In a second phase 
of NF-κB regulation, its activity is inhibited late times in MRV infection, and this is 
essential for efficient apoptosis induction [59]. This is characterized by a decrease in 
IκBα degradation.  This NF-κB inhibition sensitizes the cells to TRAIL-mediated 
apoptosis, thus allowing TRAIL and MRV induced apoptosis to occur in TRAIL resistant 
cell by utilizing the extrinsic pathway of apoptosis [59].  This NF-κB inhibition phase is 
associated with apoptosis in HEK293 cells and primary cardiac myocytes and has been 
traced to S1 gene [60].   
MRV infection also activates the intrinsic pathway of apoptosis. In MDCK cells 
overexpression of Bcl-2 (B-cell lymphoma 2) caused inhibition of MRV induced 
apoptosis [48]. Bcl-2 belongs to a family of proteins that contain both anti-apoptotic (Bcl-
2, Bcl-xL) and pro-apoptotic (Bcl-2 associated X protein (Bax), Bcl-2-antagonist/killer 
(Bak)) members. NF-κB activation is required for cleavage of Bcl-2 family member 
BH3-interacting domain death agonist (Bid) to generate tBid, which then translocates to 
the mitochondria, which results in the release of pro-apoptotic factors cytochrome c and 
Smac/DIABLO. Release of these mediators causes activation of caspase 9 and 
subsequently caspase 3 [61].  Smac binds to cellular inhibitor of apoptosis proteins 
(IAPs) and prevents their inhibitory action on caspase activity, thus promoting apoptosis 
[62].  
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Another protein NOXA is required for MRV induced apoptosis and cells lacking 
NOXA have diminished apoptosis. NOXA is induced 36-48 hours post infection and is 
dependent in IRF-3 and NF-κB [63].   
MRV infection also results in strain specific patterns of activation of the c-Jun N-
terminal kinase (JNK), extracellular-related kinase (ERK), and p38 mitogen-activated 
protein kinase (MAPK) signaling pathways [64]. T3D and T3A strain infection, but not 
TIL, in L929 cells cause activation of JNK within 10 hours and steadily increases for first 
24 hours [64]. ERK activation occurs in T3D, T3A and T1L infected cells and occurs in 
two phases. The first phase resolves in 30 min and the second phase is activated by 2 
hours post infection. Where JNK activation is required for MRV induced apoptosis, ERK 
inhibition does not inhibit apoptosis [64].  JNK is also required for efficient release of 
Smac and cytochrome c from the mitochondria in infected cells indicating that JNK 
promotes the intrinsic pathway of apoptosis in MRV infected cells [65].   
Another cellular protease, the calcium dependent papain-like neutral cysteine 
protease, calpain, also plays a role in MRV induced apoptosis. Calpain is widely present 
throughout the cytoplasm of many cell types and exists as an inactive pro-enzyme in 
steady state with its endogenous inhibitor calpastatin. Cellular calpain activity increases 
as early as 2 hours post infection in MRV infected L929 cells and in myocardiocytes. 
Calpain inhibitors blocked apoptosis induced by MRV strains T3A, T1L and UV-
inactivated MRV, indicating the role of calpain in this process [66, 67].  
MRV Infection and Host Translation Shutoff 
 MRV infection causes phosphorylation of eIF2α, a subunit of the eIF2 translation 
initiation factor that forms ternary complex with GTP and the tRNAiMet and then recruits 
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the 40S subunit of the ribosome. Once translation begins, GTP is cleaved and eIF2 is 
released. It then binds to eIF2B, which exchanges the spent GDP for GTP. This GTP 
exchange is inhibited when eIF2α is phosphorylated and thus causes eIF2 to bind to 
eIF2B more tightly [68]. This results in translation shut off and stalling of ribosomes on 
mRNA [69, 70]. This eIF2α phosphorylation in MRV infected cells is caused by the 
activation of PKR, which binds to dsRNA. Some strains of MRV prevent PKR activation 
by the binding of viral dsRNA by the viral protein σ3 [71].  The activation of PKR 
inhibits cap-dependent translation, but not viral translation which use the internal 
ribosome-entry sites (IRESs) to allow the mRNA to escape this shut off [72].  In MRV 
infected cells (most strains), at late times in infection, only the viral proteins are 
translated and host translation is inhibited [73].  Reassortment studies have implicated the 
viral protein σ3 for this shut-off and the functional difference between σ3 from strains 
that do not initiative host translation shutoff and that do, are not well understood [74].  
Infection with MRV strains that do not inhibit host translation, have the σ3 protein 
localized throughout the cell, preventing activation of PKR and subsequent shut-off. In 
strains that do cause shut-off, σ3 is believed to be localized in and around VFs, inhibiting 
translation everywhere in the cell except the VFs [75]. The exact mechanism of PKR 
activation is not known, and it has been speculated, that in case of MRV, dsRNA is not 
likely exposed to the cytoplasm [76, 77]. 
 eIF2α phosphorylation is also responsible for the formation globular, cytoplasmic 
structures called stress granules (SGs) [78]. These are formed in response to stressors 
such as heat, chemicals and viral infection [79]. SGs contain silenced mRNA, ribosomal 
subunits, translation initiation factors and several cellular proteins, some of which are 
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known to bind RNA like T-cell intracellular antigen 1 (TIA-1), TIA-1 related protein 
(TIAR), and GTP-ase binding protein (G3BP) [80, 81]. MRV also induces formation of 
stress granules through PKR, although some strains are able to prevent PKR activation by 
binding dsRNA by σ3 [71].  However, these SGs reduce in number throughout infection 
and at late times are completely absent in MRV infected cells, even though eIF2α 
phosphorylation levels remain high.  MRV infected cells are also unable to form SGs in 
the presence of other stress like sodium arsenite, suggesting that MRV is able to 
somehow disrupt or prevent the formation of SGs at later times in infection [82, 83].   
MRV Oncolysis 
 Reports of tumor regression following virus infection has been reported as early 
as the 1900s and studies on viral replication and subsequent lysis of murine experimental 
tumors documented as early as 1920 [84]. Viruses used for cancer treatment are termed 
oncolytic viruses and have been shown to have oncolytic potential in numerous human 
transformed cell lines, ex-vivo tumors and in human clinical trials. As early as 1977, the 
potential of MRV of selectively destroying transformed cell was demonstrated when 
transformed cell lines exhibited increased susceptibility to MRV [85, 86]. It being a 
clinically benign virus makes it a very attractive therapeutic for cancer treatment [87].  
The ability of MRV to infect transformed cells and not normal cells has been found to be 
independent of the cell receptors it binds [88]. Instead this characteristic was attributed to 
the presence of epidermal growth factor receptor (EGFR)	  [88], and that MRV binds to the 
N-terminal ecto-domain of the EGFR [89]. MRV infection resistant NIH-3T3 cells 
became sensitive after being transfected with a v-erb B oncogene that confirmed ligand-
independent constitute tyrosine kinase activity, showing the importance of intracellular 
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signaling rather that receptor binding of MRV [90].  Downstream of the EGFR signaling 
is the Ras pathway, which has been implicated in carcinogenesis and tumor progression 
in most tumors [91, 92]. MRV infection sensitivity was conferred in resistant NIH-3T3 
cells, which were transfected with ras or downstream Ras pathway elements [93]. It was 
also demonstrated that while virus transcription occurred in both Ras-transformed and 
untransformed NIH-3T3 cells, translation occurred only in transformed cells [93]. The 
inability to translate protein in non-transformed cell line was traced to the PKR activity 
and its antiviral defense capabilities. In Ras-transformed cells, PKR phosphorylation is 
downregulated, thus allowing MRV to replicate [93].  Another study suggests that MRV 
sensitivity is linked to the Ras/Ral guanine exchange factor (RalGEF)/p38 pathway [94]. 
Ras enhanced MRV spread in subsequent rounds of infection by suppressing viral RNA 
induced IFN-β production through negative regulation of RIG-I signaling [95]. These 
studies provide significant information linking MRV oncolysis to Ras signaling. 
Alternatively, in C26 colorectal tumor cells, MRV oncolysis was found to be independent 
of Ras status and viral replication but expression of mutated Ras increases the sensitivity 
of tumor cells to MRV induced apoptosis. [96].  It has been argued that Ras pathway is 
not responsible for selective MRV infection [97].  They saw no oncolysis in NIH-3T3 
cells, even though it had similar levels Ras as other tested cancer cell lines [97]. A study 
by Twigger et al. [98], found no association between MRV sensitivity and EGFR levels. 
ISVPs and core particles showed the same levels of infection as intact virus. In the 4 cell 
lines they tested, MRV oncolysis was unaffected by inhibition or stimulation of EGFR 
signaling. Also inhibiting downstream Ras signaling also did not abrogate MRV 
oncolysis [98]. A recent study found that MRV preferentially induces apoptosis and 
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inhibition of p21 protein in KRAS mutant colon cancer cells and acts in synergism to 
irinotecan	  [99].  Replication efficiency of all viruses is somehow dependent on the host 
cell machinery and aggressively growing cancer cells are likely to provide a suitable and 
friendlier environment for efficient virus replication and are thus more selectively 
destroyed. The molecular basis of MRV oncolysis is still not very clear and needs further 
investigation. 
Preclinical Studies of MRV Oncolysis 
 Coffey et al.	   [100] were the first to test MRV as a treatment for cancer. They 
tested 25 human cancer cell lines for MRV oncolytic activity and 20 of those were shown 
to be susceptible [100].  They also tested MRV oncolysis in SCID/NOD murine 
xenograft models, and found tumor regression in 6 out of 9 mice [100]. Following that 
there were many preclinical testing of MRV oncolysis in many different tumor types, in 
vitro and in vivo. MRV’s oncolytic capacity was successfully demonstrated in brain 
tumors [101-103], breast tumor [104, 105], colon cancer [106, 107], ovarian cancer [106], 
prostate cancer [108, 109], bladder cancer [110, 111], pancreatic cancer [112-114], lung 
cancer [115], blood cancer [116, 117] and many more. Most of these investigations were 
done in SCID/NOD mice xenograft models. A single intratumoral injection of 1 x 107 
plaque forming units (PFU) of MRV has proven to be sufficient to cure the majority of 
cancers tested.  In most of the studies, the mechanism of tumor death was found to be 
apoptosis, consistent with the general method of MRV cytotoxicity. But there is some 
evidence that MRV leads to autophagy, a cell death process, in some cancer cell lines like 
multiple myeloma in vitro [118, 119]. MRV induced autophagy in cancer cells may 
involve the ER stress, which, through the Akt-mTOR pathway, induces autophagy [119, 
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120]. MRV has also been shown to cause necrotic cell death, characterized by swelling of 
cell cytoplasm and consequent membrane destabilization and lysis, in head and neck 
squamous cells in vivo [121]. The exact mechanism of MRV induced death of remains 
controversial. MRV may cause tumor cell death by utilizing several mechanisms, such as 
apoptosis, autophagy and even necrosis.  
 MRV has also been shown to override the various mechanisms utilized by tumor 
cells to avoid immune responses, thus promoting antitumor immunity [122-124]. Since 
MRV is a common ubiquitous virus, it is common for patients to have neutralizing 
antibodies against MRV. This represents major obstacle to successful systemic delivery. 
Recently successful intravenous delivery of MRV was confirmed in a population of pre-
immune cancer patients [125]. In a phase 1b study MRV was administered intravenously 
in 10 patients 6-28 days before surgical resection of colorectal hepatic metastases. MRV 
was given as up to 5 daily infusions. MRV replication was confirmed to take place 
selectively in tumors and not in normal liver tissue [125].  Another study by Adair et al.	  
[126], found that MRV was directly cytotoxic against tumor cells but not fresh 
hepatocytes. While MRV activity was significantly inhibited in presence of neutralizing 
serum, it was protected when loaded onto peripheral blood mononuclear cells, which may 
be carrying the virus after intravenous injection into the patients.  In addition the natural 
killer (NK) cells were induced to selectively target tumor cells by MRV treatment. 
Clinical Trials with MRV  
 With successful preclinical trials in several types of cancer MRV has moved to 
human clinical trials. MRV clinical trials are conducted by a Calgary, Canada based 
company called Oncolytics Biotech, who uses MRV as “Reolysin”.  Of the 33 clinical 
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trials of Reolysin, there are 11 phase I, 4 phase I/II, 14 phase II, 3 translational and 1 
phase III studies.  More than 1000 patients have been treated with Reolysin, and till date 
no maximum tolerated dose (MTD) has been reached. Monotherapy toxicities have 
generally been mild and include chills, fever, headache, cough, myalgia, runny nose, sore 
throat, fatigue and grade 1 or 2 lymphopenia and neutropenia. The first three clinical 
trials were local monotherapy for patients with subcutaneous tumors, prostate cancer and 
recurrent malignant gliomas. These studies showed that MRV was well tolerated and 
safe, though gave moderate clinical response. To increase efficiency, MRV has also been 
tested in synergism with standard radiation or chemotherapy. These proved to be well 
tolerated by patients. All the trials have made it clear that MRV in combination with 
other therapeutics can yield maximum effect. A number of pre-clinical studies have also 
tested synergistic therapy using radiation, and chemotherapeutic agents like docetaxel, 
paclitaxel and carboplatin and have shown great promise [127-130]. 
 
Figure 2.4. Hypoxia formation. Rapidly 
growing tumor cells outgrow their blood 
supply and form condition of low 
oxygen, known as hypoxia. 
 
Hypoxia and HIF-1α  
 Oxygen is an essential element in 
the life of aerobic organisms for the 
generation of cellular energy in the form 
of ATP. Thus reduction of normal 
oxygen, termed hypoxia has its 
consequences on the cell viability. Hypoxia can either be chronic or acute. In acute 
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hypoxia, a sudden and complete reduction in blood flow leads to hypoxia, whereas in 
chronic hypoxia gradually decreasing levels of oxygen occur due to increasing distance 
from blood supply (Fig 2.4). Under chronic hypoxia there is trigger of cellular responses 
in order to survive. At molecular levels the response to hypoxia involves changes in gene  
 
Figure 2.5. Regulation by Hypoxia Inducible Factor (HIF). HIF-1α and HIF-1β, 
dimerize to form HIF-1, which binds to canonical DNA sequences in the 
promoter/enhancer region of the genes it regulates, which aid the cell in survival, 
migration, proliferation, etc. 
 
expression	  [131]. The upregulation of proteins involved in adaptation and survival in the 
hypoxic environment is controlled by the transcription factor, hypoxia inducible factor  
(HIF)	  [132] (Fig. 2.5). The HIF family is composed of three members, HIF-1, HIF-2 and 
HIF-3	   [133]. HIF-3 is not well understood. HIF-1 is ubiquitous in expression whereas 
HIF-2 is only expressed in kidney, heart, lungs and small intestine and in endothelial cells	  
[134]. HIF-1 is a heterodimer of two helix-loop-helix Per-ARNT-Sim proteins, HIF-1α 
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and HIF-1β (also known as aryl hydrocarbon nuclear translocator, ARNT). The formation 
of HIF-1 is dependent on the availability of HIF-1α, which is tightly regulated post- 
 
Figure 2.6. HIF-1α  regulation. Under normoxia, in the oxygen dependent pathway, 
HIF-1α is hydroxylated by PHD2, leading to its binding to the VHL and then ubiquitin 
dependent proteasome mediated pathways. Under hypoxia, inhibition of the PHD2 
proteins leads to its stabilization, and thus binding with HIF-1β. Independent of oxygen 
status, RACK1 and HSP90 compete to bind to HIF-1α. HSP90 binding leads to HIF-1α 
stabilization and RACK1 binding leads to degradation through the proteasome. 
 
translationally via oxygen dependent and independent degradation pathways (Fig. 2.6). In 
the oxygen dependent pathway, under normoxic conditions, HIF-1α is hydroxylated by 
oxygen sensitive prolyl hydroxylase domain (PHD2) proteins at proline residues 402 and 
564 [135, 136]. This leads to binding of von Hippel-Lindau (pVHL) protein to the HIF-
1α oxygen-dependent-degradation (ODD) domain. pVHL recruits an Elongin 
BC/Cul2/pVHL (E3) ubiquitin-protein ligase complex to HIF-1α, resulting in 
ubiquitination and degradation of HIF-1α by the 26S proteasome [137-139]. Few other 
pVHL mediated regulation pathways have been described. Osteosarcoma-9 (OS-9) 
caused downregulation of HIF-1α by forming complexes with PHD2 and HIF-
1α and targeting it the proteasome	   [140]. Another protein, spermidine/spermine-N1-
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acetyltransferase (SSAT2), stabilizes the interaction between pVHL and elongin C and 
thus promotes HIF-1α degradation	   [141]. HIF-1α is also hydroxylated by another 
oxygen-sensitive enzyme, factor inhibiting HIF-1 (FIH-1), at the asparagine residue 
(N803) in the C-terminal transcriptional activation domain to prevent interaction with 
transcriptional co-activator CBP/p300, and thus inhibits transactivational activity of HIF-
1	   [142, 143]. Under hypoxic conditions the action of PHD2 and FIH-1 is inhibited and 
HIF-1α is stabilized. When HIF-1α and HIF-1β are present, they form a dimer, 
translocate to the nucleus, and bind to canonical DNA sequences (G/ACGTG) termed 
hypoxia response elements (HREs) in the promoter or enhancer regions of target genes 
[144]. The oxygen independent pathway for HIF-1α degradation is regulated by the 
receptor for activated C kinase (RACK1) protein, which competes with heat shock 
protein 90 (HSP90) for binding to the HIF-1α PAS-A domain [145]. Binding of HSP90 
leads to stabilization of HIF-1α and binding of RACK1 to HIF-1α leads to its 
ubiquitination and proteasome mediated degradation by an E3 ubiquitin ligase complex 
[145]. Calcineurin (also known as protein phosphatase 2B) is a calcium/calmodulin-
dependent and serine/threonine-specific protein calcineurin, which promotes HIF-
1α expression by dephosphorylating RACK1 and blocking RACK1 dimerization, and 
therefore inhibiting RACK1-mediated HIF-1α degradation [146]. In addition, 
mammalian septin family member, SEPT9_v1, has been reported to bind HIF-1α and 
prevent RACK1 mediated proteasome targeting [147]. Another protein, SSAT1 binds to 
HIF-1α and RACK1 and promotes HIF-1α ubiquitination [148]. Besides these chief 
degradation pathways operational under normoxic conditions, few circumstances where 
HIF-1α is subjected to ubiquitin-independent degradation by the proteasome have been 
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described. One is its constitutive degradation during chronic hypoxia where HIF-1α is 
subjected to a basal turnover with a half-life of 2–4 h. Its proteasomal degradation 
requires an intact ODD domain. However, neither prolyl hydroxylation nor recognition 
by VHL or ubiquitination is required for addressing it to the proteasome [149]. The other 
is destabilization by histone deacetylase inhibitors. Under standard conditions, proper 
folding of HIF-1α requires the sequential action of the HSP70 and HSP90 chaperones. 
Upon inhibition of HDACs, HSP90 becomes acetylated and loses its activity. The 
interruption of the HSP70/HSP90 axis leads to the presenting of newly synthesized HIF-
1α to the proteasome where it is degraded independently of any prior ubiquitination 
[150]. Another study reports SHARP1 binding to HIF-1α and presenting it to the 
proteasome independent of ubiquitination [151]. In addition to these, a number of other 
pathways describe HIF-1α regulation independent of VHL, and either dependent or 
independent of ubiquitination [152-154].  
 Hypoxia related proteins and HIF-1α have also been found to be regulated by 
micro-RNAs (miRNAs). miR-210 was found to stabilize HIF-1α by repressing glycerol-
3-phosphate dehydrogenase 1-like (GPD1L), which reduces hyperhydroxylation	   [155]. 
Similarly, miR-424 was found to suppress cullin 2 (cul2), an active component of the 
ligase system that causes HIF-1α downregulation	   [156]. In addition, downregulation of 
some miRNAs like miR-20b, miR-199 and miR-17-92 by hypoxia caused the 
stabilization of HIF-1	  [157-159]. 
 General protein translation in the cell is shut-off during hypoxic stress in order to 
decrease energy consumption. In spite of this, few proteins crucial for cell survival, 
including HIF-1α is still translated. How HIF-1α escapes this translational shut-off is not 
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well understood. One evidence suggests the presence of internal ribosome entry site 
(IRES) in the HIF-1α mRNA, which allows translation to occur without the need of cap-
binding complex [160]. This is still disputed [161], and the protein translation is 
attributed to a cryptic promoter activity. Another study showed that during hypoxia, 
RNA-binding proteins polypyrimidine tract-binding protein (PTB) and human antigen R 
(HuR) binds 3’ and 5’ UTR of HIF-1α and enhances its translation [162]. Although, it is 
known that HIF-1α is still translated under stress induced translation shut-off, the exact 
mechanism is still not clear. 
Hypoxia in Cancer 
 Outgrowth from the blood supply and abnormal vascularization leads to hypoxia 
within solid tumors. Solid tumors often become hypoxic as the usual tissue vasculature 
can only support tumor growth within a diameter of ∼2 mm [163].  Disease progression 
and mortality in cancer patients is often correlated with the presence of chronic or 
transient hypoxic within tumors [164-166]. Hypoxia is accompanied by stabilization of 
HIF-1α.  Impact of HIF-1α expression on the prognosis of many cancers has been 
studied. They strongly correlate with poor survival in head and neck [167], esophagus 
[168], stomach [169], lung [170] and other types of cancer. HIF-1 regulates many genes, 
main of which are genes regulating angiogenesis and metabolic pathways that help adapt 
the cell to reduced O2. It also exerts a selection pressure for cells carrying mutation that 
can inactivate apoptosis and increase cell survival [171, 172]. These mutations may cause 
permanent changes that can be maintained even in the absence of hypoxia, inducing 
resistance to other drugs and therapy. Upregulation of these genes in turn leads to 
increased tumor invasion and metastasis, resulting in disease progression and poor 
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clinical outcome [173, 174]. Hypoxia also enhances vasculogenesis [175], epithelial-to-
mesenchymal transition [176], receptor tyrosine kinase-mediated signaling [177] and also 
suppresses immune reactivity [178]. It also leads to downregulation of DNA repair 
pathways [179] and increased reactive oxygen species (ROS) generation and thus causes 
genomic instability [180]. Moreover, hypoxic tumor cells are often resistant to 
chemotherapy and radiotherapy, posing further challenges to the development of 
treatments that will lead to a complete cancer therapy [181, 182]. Resistance to radiation 
therapy occurs, as the ionizing radiation, which induce DNA breaks requires the 
availability of free oxygen radicals. Several chemotherapy agents also rely on free 
oxygen for activation, and therefore do not work under hypoxic conditions. The 
compelling evidence for hypoxia in tumors and its importance makes hypoxia a high 
priority for efficient cancer therapy.  
 Development of bioreductive prodrugs that get activated by enzymatic reduction 
in hypoxic cells is one way to target hypoxia (reviewed in [183]). Under hypoxia, 
chemical moieties such as nitro groups, quinones, aromatic N-oxides, transition metals 
and aliphatic N-oxides have the potential to be metabolized by enzymatic reductions. 
These prodrugs are either activated under moderate hypoxia or only under severe 
hypoxia. Another approach is the development of molecule inhibitors of specific targets 
if hypoxic cells, most important of which is the HIF-1.  Other inhibitors are made to 
target some HIF-1 target gene products, the mTOR pathways and unfolded protein 
response (UPR) [183]. Both of these methods face significant challenges, such as off-
target effects and drug penetration. There is still a long way to go in terms of acquiring 
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effective therapy options, which successfully target hypoxia including targeted therapy 
for individual patients. 
Oncolytic Viruses and Hypoxia 
 Tumor microenvironment such as hypoxia plays a critical role in replication, 
spread and oncolytic activity of oncolytic viruses [184, 185]. Many naturally occurring 
viruses like MRV such as Newcastle disease virus (NDV) and vesicular stomatitis virus 
(VSV) are oncolytic viruses. Some are generated via genetic engineering for enhanced 
oncolytic activity. For oncolytic viruses to be very effective they must efficiently and 
selectively replicate in tumor cells to which they would not be exposed in a natural 
course of infection, and to adapt to hypoxic environment for successful replication and 
oncolysis. Stress like hypoxia and viral infection, induce cellular response of shutting off 
translation. Since all viruses depend on host translational machinery for translation, 
hypoxic state of the infected cell critically impacts viral life cycle. This raises concerns 
that hypoxic conditions in cells could also diminish the efficacy of oncolytic viruses. The 
first engineered oncolytic virus for hypoxic tumor was an Adenovirus [186]. The early 
region 1A (E1A) gene of the Adenovirus was controlled by an HRE-containing promoter, 
thus correlating the virus’s ability to replicate and kill hypoxic tumor cells [186]. Studies 
with wild type Adenovirus found that it was unable to replicate under hypoxic conditions 
and also impact the lytic potential of the virus [187, 188].  In contrast oncolytic Herpes 
Simplex Virus (HSV), was found to have enhanced replication under hypoxic condition 
in vitro and in vivo [189, 190].  Similar results were seen with the Lister strain Vaccinia 
virus (VACV).  Hypoxia did not affect the viral protein production but resulted in higher 
virus induced cytotoxicity [191].  Vesicular Stomatitis Virus (VSV) was able to replicate 
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under hypoxic conditions but was inhibited in VHL-/- renal cell carcinoma cells, which 
have elevated levels of HIF [192, 193]. One previous study suggested that MRV infection 
leads to reduced levels of HIF-1α in hypoxic lung, colon, and renal tumor cells in a 
manner dependent on proteasome inhibition but independent of VHL expression. This 
study also suggested that MRV protein expression was inhibited in VHL-/- cells that 
constitutively express HIF-1α and that MRV infection induced cell death through the 
activation of caspase 8 and apoptosis [194].  In contrast, another study showed that MRV 
infection caused stabilization of HIF-1α and induced apoptosis in a caspase independent 
mechanism in human glioblastoma cell lines [195]. These studies indicate that the effects 
of MRV on the hypoxic response and cell death in tumor cells is cell type specific and 
thus findings from one tumor type cannot be applied to another.  
Prostate Cancer  
 Prostate cancer is the second leading cause of cancer death in men in the United 
States [196]. The prostate glands depend on androgens, testosterone and 
dihydrotestosterone (DHT) for growth and differentiation. Growth-latent maintenance of 
the prostate occurs in the presence of high levels of androgens after puberty, but upon 
development, prostate tumors again become reliant on testosterone for growth. The 
androgen receptor (AR), a ligand-activated transcription factor, facilitates androgen 
signaling and is therefore a vital protein in PCa progression [197]. AR has a large 
amino‑terminal transactivation domain, a carboxy‑terminal ligand-binding domain, a 
central DNA-binding domain and a hinge region between the DNA-binding domain and 
ligand-binding domain that is used for nuclear localization and degradation	  [198, 199]. In 
the absence of ligand, the AR is located mostly in the cytoplasm where it associates with 
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heat shock proteins (HSP)-90, -70, -56, cytoskeletal proteins and other chaperones [200]. 
Upon androgen binding, the AR translocates into the nucleus, undergoes conformational 
changes and, as a homodimer, binds to specific recognition sequences (androgen 
response elements or ARE) in the promoter or enhancer regions of target genes 
promoting their transcription. AR recruits coactivator proteins by AR, which increase the 
transcription rate and facilitates the growth of cancerous cells [201]. Thus hormone 
therapy or androgen deprivation therapy (ADT), which is achieved by blocking androgen 
production, either surgically or chemically (by using Luteinizing hormone-releasing 
hormone (LH-RH) agonist or estrogen) or by using either anti-androgens (such as 
flutamide or bicalutamide), which directly inhibit the AR, or chemicals (such as 
Goserelin acetate sold as Zoladex from AstraZeneca), which block androgens is an 
effective treatment for PCa. This treatment arrests the disease in the majority of cases, as 
evidenced by decrease in prostate specific antigen (PSA), a well-accepted marker for the 
diagnosis and prognosis of PCa, and a functional biomarker of AR activation [202].  
Figure 2.7. Androgen Receptor in 
PCa. Binding of AR with the 
androgen (DHT) causes 
conformational changes in AR and 
translocation into the nucleus, and 
along with coactivators, bind to 
DNA sequences called AREs, and 
regulated proteins such as PSA and 
also proteins needed for growth and 
survival. 
 
However, relapse in the form of 
androgen-independent PCa tumor 
growth occurs within an average of 3 years following the beginning of androgen 
 33  
deprivation. This androgen independent growth stage of PCa, also known as castration-
resistant prostate cancer (CRPC), responds inadequately to currently available treatments 
such as docetaxel and prednisone and is associated with metastasis and poor prognosis 
[203]. CRPC occurs due to a selection pressure on PCa cells to maintain AR activity. 
These selection pressures establish themselves in several ways, including amplification at 
the AR locus and thus AR overexpression [204-206], expression of splice variants of AR 
with missing an intact ligand-binding domain for androgen binding, and selection for 
somatic mutations that maintain AR activity by converting antagonistic drug responses to 
agonist responses [207, 208]. Moreover, studies have linked the AR with the emergence 
of androgen independent cells by determining that ectopic expression of high levels of 
AR can transform androgen dependent cells to androgen independence [209]. 
Additionally, adapting LNCaP cells to low hormone levels induces increased AR 
mutations [210]. Determining the AR as a acceptable therapeutic target for CRPC 
changed the emphasis of drug development towards AR targeting and drugs such as 
Enzalutamide (marketed as Xtandi by Medivation), which inhibits AR signaling were 
recently approved for treating CRPC [211]. 
Hypoxia in Prostate Cancer  
 Tumor micro-circulation suffers from damaged and erratic blood flow and 
increased vascular permeability [212]. An inefficient blood flow and lack of oxygen may 
be considered a hindrance in tumor growth, but surprisingly it is instead a protective 
characteristic and prevents complete destruction of the tumor. Hypoxia in prostate tumor 
has been shown to correlate significantly to clinical stage and predict biochemical failure 
in patients with prostate cancer	  [213, 214]. 
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 In PCa, hypoxia has been found to influence disease progression, [150] increase 
gene instability, and inhibit apoptosis induction [215]. Hypoxia selects for cancer cells 
with defective mitochondrial apoptosis pathway and Bcl-2 expression	   [216]. Akt, in its 
phosphorylated, active form, is one of the key regulators of protection of prostate tumor 
cells from apoptosis via inhibition of pro-apoptotic proteins such as Bax and BAD	  [217, 
218]. Phosphorylated Akt also inhibits the death caspase 9 by phosphorylation and hence 
directly inhibits apoptosis [219]. Akt activation is also a positive regulator of hypoxic 
response through stabilization of HIF-1α and NFκB	   [220].  Bax translocation to the 
mitochondria is also inhibited during hypoxia due to suppression of inhibitor of apoptosis 
protein 2 (IAP2) by NFκB, which in turn is activated by the PI3K/Akt pathway	   [221, 
222]. 
Hypoxia and Androgen Receptor 
 In PCa, hypoxia leads to augmented AR activity and sensitivity leading to PCa 
growth under very low hormone concentrations [223]. The process of castration caused 
drastic reduction in blood flow to the prostate tumor and activated the hypoxic signaling 
[223]. The transition from androgen-dependence to androgen-independence in PCa is a 
critical event. Relapsed CRPC strongly expresses HIF-1α, suggesting that castration-
resistant tumor cells exist under hypoxic conditions [224]. Skov et al. [225] found that 
30% of androgen dependent cells were hypoxic. This dropped to 2% 7 days after 
castration, but 50% of the androgen independent cells were again hypoxic, thus 
demonstrating that hypoxia was reduced right after castration but again increases with the 
development of CRPC. HIF-1α protein expression was activated in androgen sensitive 
LNCaP cells by DHT, which was blocked by bicalutamide, an anti-androgen	   [226]. 
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Numerous studies suggest that HIF-1α works with the AR to activate the expression of 
several genes related to tumor angiogenesis, invasion, and progression (Fig 
2.8). Moreover, crosstalk between AR and HIF-1α has been described, and the PSA gene 
contains both  
 
Figure 2.8. Hypoxia and the AR in PCa. HIF-1α and AR in association with each other 
regulate pathways leading to growth, survival and apoptosis resistance. It also is vital for 
progression to androgen independence. PI3K/Akt pathway regulates both the AR and 
HIF-1α and plays a major role in apoptosis resistance. This pathway is inhibited tumor 
suppressor gene PTEN, which is usually mutated or deleted in PCa. 
 
an ARE and a HIF response element (HRE) [227]. Thus, hypoxia may assist disease 
progression through a synergistic effect of HIF-1 and the AR to increase the expression 
of PSA, which itself has been reported to have a role in metastasis and migration [228]. 
In addition, hypoxia has been shown to influence androgen resistance and progression to 
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CRPC [215]. Amplification of many hypoxia-inducible genes, which stimulate tumor 
growth, may be caused by the residual androgen left after ADT. A recent paper studied 
the effect of HIF-1α on CRPC and found that HIF-1α is likely to contribute to metastasis 
and chemo-resistance of CRPC and inhibition of HIF-1α may increase the responsiveness 
of CRPCs to chemotherapy [229].  
 Another pronounced feature common in both androgen independent and hypoxic 
prostate tumors is the mutation or deletion of the tumor suppressor gene phosphatase and 
tensin homolog (PTEN) [230, 231]. PTEN inhibits the phosphoinositide 3-kinase/serine 
threonine protein kinase B (PI3K/AKT) pathway by dephosphorylating phosphoinositide-
3,4,5 triphosphate (PIP3). PIP3 is responsible for recruiting the Akt/PKB kinases to the 
cell membrane, driving their conformational changes and ensuing in their 
phosphorylation by phosphoinositide-dependent kinase 1 (PDK1) [232, 233]. The 
PI3K/Akt pathway in turn regulates the stimulation of cell cycle progression, survival, 
migration and metabolism. Thus, the loss of PTEN activity correlates with high Akt 
activity leading to apoptosis resistance and tumor growth in PCa [218, 234, 235]. 
Hypoxia and PI3K/Akt signaling have been reported to be both regulated, and induced by 
each other [166, 231, 236, 237]. The serine/ threonine kinase proto-oncogene, Pim-1, is 
regulated by STAT factors by Interleukin-6 (IL-6) and is involved in IL-6 induced 
activation of the AR	  [238]. In addition, Pim-1 is also tightly regulated by hypoxia	  [239]. 
Consequently, increased expression of Pim-1 may be a key factor in CRPC emergence. 
Therefore it is clear that hypoxia and HIF-1α play a key role in various stages of prostate 
tumor growth and its progression from androgen-sensitive to CRPC. It is therefore clear 
that manipulation of one target will influence another and while therapies targeting 
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hypoxia is increasing, combinational approach towards hypoxia and other conventional 
targets appears to be viable strategy for the complete management of PCa. 
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ABSTRACT 
 Outgrowth from the blood supply and abnormal vascularization leads to poor 
oxygenation, or hypoxia, within solid tumors.	  Hypoxia has emerged as one of the most 
important drivers of tumor aggression, metastasis, and poor clinical outcome in many 
cancers.	   In prostate cancer (PCa), hypoxia has been strongly correlated to biochemical 
failure and local recurrence following treatment in the absence and presence of 
neoadjuvant hormone therapy. However, current PCa treatment options do not address 
hypoxic cells highlighting a critical gap in existing therapies and the need for the 
identification, characterization, and development of therapies that target hypoxic prostate 
tumor cells. Mammalian Orthoreovirus (MRV) is a potent oncolytic virus that targets 
tumor cells over normal cells which has been shown to be safe and effective against a 
number of cancers in vitro, in animal models, and in human clinical trials. We found that 
MRV	  infects	  and	  replicates	  in	  hypoxic	  prostate	  tumor	  cells	  to	  levels	  comparable	  to	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normoxic	  cells	  leading	  to	  apoptosis	  and	  cell	  death.	  In	  addition,	  the regulatory subunit 
(HIF-1α) of the master transcriptional regulator of hypoxia, HIF-1, was significantly 
downregulated in infected cells. HIF-1α downregulation was found to occur via 
ubiquitin-dependent proteasome-­‐mediated	   degradation	   and	   translational	   inhibition.	  Virus-­‐mediated	   HIF-­‐1α	   degradation	   required	   the	   HIF-­‐1α	   PAS	   domain	   and	  expression	  of	  the	  receptor	  for	  activated	  kinase	  C	  (RACK1)	  protein.	  These data provide 
evidence that MRV may be a viable therapeutic option for targeting hypoxic cells and 
HIF-1α in PCa. 
INTRODUCTION 
Disease progression and mortality in cancer patients is often correlated with the 
presence of chronic or transient hypoxic microregions within tumors [1-3]. Hypoxia 
induced changes can lead to tumor propagation through the selection of hypoxia-adapted 
mutant cells. Cells develop hypoxia adaptation through the upregulation of genes 
encoding proteins that promote proliferation, apoptosis resistance, and angiogenesis [4, 
5]. Upregulation of these genes in turn leads to increased tumor invasion and metastasis, 
resulting in disease progression and poor clinical outcome [6, 7]. Moreover, hypoxic 
tumor cells are often resistant to chemotherapy and radiotherapy, posing further 
challenges to the development of treatments that will lead to a complete cancer cure [8, 
9].  
Prostate cancer (PCa) is the second leading cause of cancer death in men in the 
United States [10]. Therapies, in the form of surgical removal and radiotherapy, have 
undesired side effects such as impotency and urinary incontinence [11]. Hormone 
therapy, consisting of surgical or chemical deprivation of androgen, is an additional 
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treatment option for PCa patients. However, most prostate tumors develop androgen 
resistance within one to three years of therapy onset and resume growth. Detection of 
molecular markers of hypoxia in prostate tumors has been linked to progression, poor 
prognosis, low survival rate and early biochemical relapse [12, 13]. Considering that 
prostate tumors extract benefit from poor oxygenation for survival and metastasis, there 
is a crucial need for the development of therapeutics targeting hypoxic PCa cells.  
The upregulation of proteins involved in adaptation and survival in the hypoxic 
environment is controlled by the transcription factor, hypoxia inducible factor 1 (HIF-1). 
HIF-1 is a heterodimer of two helix-loop-helix Per-ARNT-Sim proteins, HIF-1α and 
HIF-1β. When HIF-1α and HIF-1β are present, they form a dimer, translocate to the 
nucleus, and bind to canonical DNA sequences termed hypoxia response elements 
(HREs) in the promoter or enhancer regions of target genes [14]. The formation of HIF-1 
is dependent on the availability of HIF-1α, which is tightly regulated post-translationally 
via oxygen-dependent and -independent degradation pathways. Under normoxic 
conditions, HIF-1α is hydroxylated by prolyl hydroxylase 2 (PHD2) protein at proline 
residues 402 and 564 [15, 16]. This leads to binding of von Hippel-Lindau (pVHL) 
protein to the HIF-1α oxygen degradation domain. pVHL recruits an E3 ubiquitin-protein 
ligase complex to HIF-1α, resulting in ubiquitination and degradation of HIF-1α by the 
26S proteasome [17-19]. Under hypoxic conditions the action of PHD2 is inhibited and 
HIF-1α is stabilized. An oxygen-independent pathway for HIF-1α degradation is 
regulated by the receptor for activated C kinase (RACK1) protein, which competes with 
heat shock protein 90 (HSP90) for binding to the HIF-1α PAS domain [20]. Binding of 
HSP90 leads to stabilization of HIF-1α and binding of RACK1 to HIF-1α leads to its 
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ubiquitination and proteasome mediated degradation by an E3 ubiquitin ligase complex 
[20].  
Mammalian Orthoreovirus (MRV) is a clinically benign, double stranded RNA 
family Reoviridae member that is not associated with major pathogenicity in humans or 
other animals. MRV is an oncolytic virus that preferentially replicates in tumor cells over 
normal cells [21]. Successful demonstration of MRV oncolytic activity against numerous 
cancer types in animal models [22-24] led to its development and clinical testing as a 
cancer therapy in a number of Phase I/II/III human clinical trials. It has emerged as a safe 
and effective therapy for a number of cancer types leading to disease stabilization and 
tumor regression in many patients [25-28]. With regards to PCa, MRV specifically 
replicates in and kills PCa cells in vitro, in an in vivo animal model, and in human 
patients [29, 30]. 
Little is known about the impact of MRV infection on hypoxic tumor cells. One 
previous study suggested that MRV infection leads to decreased levels of HIF-1α in 
hypoxic lung, colon, and renal tumor cells in a manner dependent on proteasome 
inhibition but independent of VHL expression. This study also suggested that MRV 
protein expression was inhibited in VHL-/- cells that constitutively express HIF-1α and 
that MRV infection induced cell death through the activation of caspase 8 and apoptosis 
[31].  In contrast, another study showed that MRV infection stabilized HIF-1α and 
induced apoptosis in a caspase independent mechanism in human glioblastoma cell lines 
[32]. These studies clearly indicate that the effects of hypoxia on MRV infection and the 
effects of MRV on the hypoxic response and cell death in tumor cells growing under 
hypoxic conditions is cell type specific and thus findings from one tumor type cannot be 
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applied to another. A comprehensive investigation of MRV replication under hypoxic 
conditions, and the mechanisms involved in MRV-induced HIF-1α regulation were not 
done in either of these prior studies. The objectives for this study were to examine MRV 
replication, impact on the hypoxic response, and induction of tumor cell death of three 
prostate tumor cell lines that vary in both androgen sensitivity and metastatic potential 
grown under normoxic and hypoxic conditions. We found that MRV readily replicates in 
and kills prostate tumor cells growing in hypoxic conditions, and further, that HIF-1α 
protein levels and activity are downregulated in MRV infected prostate tumor cells. We 
additionally provide evidence that in PCa cells, MRV-induced HIF-1α degradation 
requires the HIF-1α PAS domain, and is inhibited following siRNA knockdown of 
RACK1, suggesting that MRV induces HIF-1α degradation through the RACK1 
pathway. These findings represent an important step in the characterization of MRV 
oncolytic treatment as a therapy for killing hypoxic adapted prostate tumor cells. 
MATERIALS AND METHODS 
Cells and reagents DU145 cells were maintained in Eagle's modified essential medium 
(Invitrogen), PC3 cells were maintained in F-12K media, and LNCaP cells were 
maintained in RPMI media (ATCC), containing 10% fetal bovine serum (Atlanta 
Biologicals) and penicillin-streptomycin (100 IU/ml, Mediatech). L929 cells were 
maintained in Joklik’s minimal essential medium (Irvine Scientific) containing 2% 
bovine calf serum, 2% fetal bovine serum (Atlanta Biologicals), 2 mM L-Glutamine 
(Mediatech) and penicillin-streptomycin (100 IU/ml, Mediatech). All cell lines were 
obtained from the American Type Culture Collection. Primary antibodies used were as 
follows: mouse monoclonal anti-RACK1 (BD Biosciences), mouse monoclonal anti-HIF-
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1α (Becton, Dickinson and Company Biosciences), rabbit polyclonal anti-β-actin (Cell 
Signaling Technologies), rabbit monoclonal anti-PARP (Cell Signaling Technologies), 
rabbit polyclonal anti-µNS [33], and mouse anti-HA (Cell Signaling Technologies). 
Secondary antibodies used for immunoblot experiments were alkaline phosphatase (AP)-
conjugated goat anti-mouse or anti-rabbit IgG (Bio-Rad). Secondary antibodies used in 
immunofluorescence experiments were Alexa 488-conjugated donkey anti-mouse, and 
Alexa 594-conjugated donkey anti-rabbit immunoglobulin G (IgG) antibodies 
(Invitrogen). Proteasome inhibitor, MG132 (Enzo Life Sciences), was used at a final 
concentration of 10 µM, cobalt chloride (CoCl2) at a final concentration of 500 µM and 
NSC 632839 hydrochloride (F6) (BostonBiochem) at a final concentration of 30 µM. 
Infection	  MRV	  virions	  (T3D	  strain)	  are	  from	  our	  laboratory	  stocks.	  Purified	  virions	  were	  prepared	  as	  described	  [34],	  using	  Vertrel	  reagent	  (DuPont)	  in	  place	  of	  Freon,	  and	  stored	   in	  dialysis	  buffer	   (150	  mM	  NaCl;	  10	  mM	  Tris	  pH	  7.4;	  10	  mM	  MgCl2)	  at	  4°C.	  Cells were seeded onto 60-mm, 35-mm, or 9.6-cm2 cell culture dishes 24 h before 
infection. Cells were infected with MRV virions at a cell	   infectious	   unit	   (CIU)	   of	   1	  based	  on	  titers	  determined	  on	  cell	  lines	  used	  as	  previously	  described	  [35].	  	  
Hypoxia	  Hypoxic	  conditions	  were	  obtained	  by	  incubating	  cells	  in	  1%	  O2	  and	  5%	  CO2	  at	   37°C in a Galaxy 48R CO2 Incubator (New Brunswick Scientific) equipped with 1-
19% O2 controls. All cells were adapted to hypoxia for 4 h prior to infection. 
Immunoblotting Cells were lysed in 100 µL 2X SDS protein loading buffer (125 mM 
Tris.HCl [pH 6.8], 200 mM DTT, 4% SDS, 0.2% Bromophenol blue, 20% Glycerol). 
Immunoblots were performed as previously described [35]. Blots were exposed to Lumi-
PhosTM WB Chemiluminescent Substrate (Thermo Scientific), and images were collected 
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and quantified using a ChemiDoc XRS camera and QuantityOne software (Bio-Rad). All 
experiments were independently performed at least 3 times and representative results are 
shown. 
Immunofluorescence Cells were fixed and processed for immunofluorescence as 
previously described [33]. Samples were imaged with a Zeiss Axiovert 200 inverted 
microscope equipped with fluorescence optics. Images were prepared using Photoshop 
and Illustrator software (Adobe Systems). All experiments were independently performed 
at least 3 times and representative results are shown. 
Virus Replication Assay Samples were harvested and subjected to 3 freeze thaw cycles. 
Serial ten-fold dilutions in phosphate-buffered saline (PBS) (137 mM NaCl, 3 mM KCl, 
8 mM Na2HPO4 [pH 7.5]) containing 2 mM MgCl2 were made and plaque forming units 
(PFU) were determined by standard plaque assay on L929 cells [36]. The experiment was 
done thrice independently and the average of the three experiments was plotted on a bar 
graph with error bars depicting the standard error of the averages. 
Quantitative Real-Time PCR RNA was harvested using Trizol (Invitrogen) as per 
manufacturer’s instruction. 1 µg RNA was treated with DNAase I (New England 
Biolabs) then used to make cDNA with Superscript III Reverse Transcriptase 
(Invitrogen) as per manufacture’s protocol. Primers used were as follows: β-actin (409 
bp), the forward primer was ACCAACTGGGACGACATGGAGAAA and the reverse 
primer was TTAATGTCACGCACGATTTCCCGC; HIF-1α (564 bp), the forward 
primer was GAACCTGATGCTTTAACT and the reverse primer was 
CAACTGATCGAAGGAACG. The cDNA was amplified by qPCR using 0.1 µM 
primers, 0.7X SYBR green, 200 µM dNTP, 1X GoTaq Reaction Buffer, 1.25 U GoTAQ 
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polymerase (Promega) and 2 µL of reverse transcription reaction mixture as template in 
an Opticon cycler (Biorad). The C(t) value of HIF-1α was averaged using the C(t) value 
of β-actin and plotted on a graph. The experiment was done thrice independently and 
each experiment included 2 replicates. The average of the three experiments was plotted 
on a bar graph with error bars depicting the standard error of the averages. 
Transfection Commercially available control and RACK1 specific siRNAs (Cat. No. 
4392421-s20342, s20341, Ambion) were complexed with Lipofectamine 2000 
(Invitrogen) according to the manufacturer’s protocol and added to cell suspension 
prepared by trypsinization in 1 mL of Opti-MEM. After 4 hours incubation, 1 mL of 
Eagle’s MEM with 20% FBS and no antibiotics was added. After 24 h incubation at 
37°C, new siRNA:Lipofectamine 2000 complexes were prepared and added to the 
transfected adherent cells. Following a 24 h incubation in normoxic conditions, 
transfected cells were mock-infected or infected with MRV and incubated in either 
normoxic or hypoxic conditions for 12 or 24 h, at which point cells were harvested and 
lysed in protein loading dye and subjected to immunoblot analysis. Blots were exposed to 
Lumi-PhosTM WB Chemiluminescent Substrate (Thermo Scientific), and images were 
collected and quantified using a ChemiDoc XRS camera and QuantityOne software (Bio-
Rad). The experiment was repeated independently 3 times and representative results are 
shown. Plasmid transfection was performed using TransIT-LT1 (Mirus) as per 
manufacturer’s protocol. 
Viability and caspase activity assay Cells were subjected to the ApoTox-Glo Triplex 
Assay (Promega) or Caspase 8/9 Glo Assay (Promega) according to the manufacturer’s 
protocol. Fluorescence and luminescence was recorded using GloMax Multi+ microplate 
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reader (Promega). Graphs were constructed using Microsoft Excel. Results shown are the 
average and standard deviation of three experimental replicates. Statistical significance 
was calculated using averages of 3 experimental replicates. 
Plasmid Construction A firefly luciferase reporter plasmid (pGL4.26 luc2/minP/Hygro) 
was purchased from Promega. Upper and lower oligonucleotides were designed which 
contain three copies of the hypoxia response element [37], 5ʹ′ GTACGTGCT 3ʹ′, flanked 
on each end by NheI and HindIII restriction sites (New England Biolabs). 
Oligonucleotides were annealed and ligated into NheI and HindIII digested pGL4.26 
luc2/minP/Hygro to create pHRE-HIF-1α. pHA-HIF-1α [Addgene plasmid 18949, [38]] 
and pHA-HIF-1α P402A/P564A [Addgene plasmid 18955, [39]] were obtained from Dr. 
William G Kaelin, Addgene. pHA-HIF-1α ΔPAS was created by HindIII digestion of 
pHA-HIF-1α to remove aa 85-298 containing the PAS domain. A synthetic double-
stranded DNA flanked on the end with BamH1 and AgeI digestion sites and containing 
HIF-1α nt 1-1096, with the PAS domain (nt 253-894) deleted was purchased (gBlock, 
Integrated DNA Technologies), digested with BamHI and AgeI, and ligated into the 
digested pHA-HIF-1α. Following ligation, transformation, and screening, all plasmids 
were verified by sequencing.  
Luciferase Assay Cells were transfected with pHRE-HIF-1α using Lipofectamine 2000 
(Invitrogen) according to the supplier’s protocol. Luciferase expression was measured 
using the One-Glo Luciferase Assay Kit and the luminescence function of a GloMax 
Multi+ microplate reader (Promega). Following recording of luminescence, cells were 
lysed and total protein measured using Bradford Assay (Biorad) and the absorbance 
function of a GloMax Multi+ microplate reader. Luminescence levels were normalized to 
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total protein and plotted on a graph. Results shown are means and standard deviation of 
three experimental replicates. The statistical significance was calculated using the 
average of 3 experimental replicates. 
L-Azidohomoalanine (L-AHA) protein labeling and precipitation 50 μM L-AHA 
(Invitrogen) was added to cells at 6 or 18 h p.i. then cells were harvested in lysis buffer 
(1% SDS in 50 mM Tris-HCl, pH 8.0) at 12 h or 24 h p.i., respectively. L-AHA-labeled 
proteins were conjugated with biotin as per manufacture’s protocol. Following 
conjugation, proteins were precipitated and resuspended in 100 μL lysis buffer, diluted to 
800 µl in Tris-buffered saline (20 mM Tris, 137 mM NaCl [pH 7.6]) containing 0.1% 
Tween (TBS-T) and incubated for 2-3 h at room temperature with streptavidin magnetic 
beads (Pierce) prepared as per manufacturer’s instruction. Beads were collected and 
washed 6 times with TBS-T, then suspended in 2X SDS protein loading buffer for 
immunoblot analysis. 
Statistical Analysis Statistical significance was determined using student’s t-test and 
two-tailed p value calculated with GraphPad software. Differences in groups for which 
p<0.05 were considered to be statistically significant and are indicated with an asterisk in 
the figures. 
RESULTS 
MRV is translationally active and replicates in hypoxic tumor cells. Hypoxia-induced 
shutoff of protein synthesis negatively impacts the ability of some oncolytic viruses to 
replicate in tumor cells growing in hypoxic environments [40, 41]. Because MRV 
mRNAs escape host translational shutoff induced by infection, [42], we hypothesized that 
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MRV may replicate in prostate tumor cells growing in a hypoxic environment. To test 
 
Figure 3.1. Hypoxia does not interfere with MRV translation or replication in 
prostate tumor cells. DU145, PC-3 and LNCaP prostate tumor cells were mock-infected 
or infected with MRV T3D and incubated under normoxic or hypoxic conditions. 4 h 
prior to infection, CoCl2 was added to cells where indicated.  A) At indicated times, cells 
were harvested and proteins were separated on SDS-PAGE and transferred to 
nitrocellulose. Blots were immunostained with rabbit α-µNS polyclonal antiserum or 
rabbit β-actin polyclonal antibodies followed by AP-conjugated goat α-rabbit IgG 
secondary antibodies. 1B) At 0, 6, 12, 18, and 24 h p.i., cells were harvested and 
subjected to three freeze/thaw cycles. Standard virus plaque assays on L929 cells were 
performed on cell lysates to determine virus titer (PFU). Mean of the relative PFU/ml 
from three independent experiments is plotted and the error bars represent the standard 
deviation (SD). 
 
this hypothesis, we examined MRV infection in normoxic and hypoxic prostate tumor 
cell lines. We examined three cell lines that represent androgen-resistant, moderate 
metastatic (DU145), androgen-resistant, high metastatic (PC-3), and androgen-sensitive, 
low metastatic (LNCaP) prostate tumor cells. In addition to growth in hypoxic conditions, 
samples were treated with cobalt chloride (CoCl2), which mimics hypoxia in the cell by 
inhibiting PHD2 hydroxylation of HIF-1α [43]. Each cell line was infected with MRV 
and grown in normoxic or hypoxic conditions. At 24 h p.i., immunoblots against virus 
non-structural protein µNS were performed to examine MRV protein synthesis.  We 
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observed that virus protein translation was not substantially changed by growth under 
hypoxic relative to normoxic conditions, suggesting the virus was able to enter and 
initiate infection in hypoxic prostate tumor cells (Fig. 3.1A). To examine the impact of 
hypoxia on viral replication, we infected each cell line with MRV under normoxic or 
hypoxic conditions. Samples were harvested at 6 h intervals and plaque assays were 
performed to measure virus titers. We found that virus growth was not significantly 
different in hypoxic relative to normoxic conditions in any of the tested cell lines (Fig. 
3.1B). Thus we established that MRV productively enters, translates protein, and 
replicates in diverse hypoxic prostate tumor cell lines in a manner indistinguishable from 
that measured in normoxic tumor cells. These data suggest that hypoxic conditions do not 
interfere with successful MRV infection in prostate tumor cells. 
MRV infection results in diminished HIF-1α  protein levels and activity in hypoxic 
prostate tumor cells.  In separate prior studies, MRV infection was found to induce an 
increase in HIF-1α proteasome-mediated degradation in lung-, renal-, and colon-derived 
cancer cells [31] but to induce a decrease in HIF-1α degradation in brain-derived tumor 
cells [32], suggesting MRV infection has variable effects on the cellular hypoxic 
response depending on tumor type. To determine if HIF-1α expression was altered by 
MRV infection in hypoxic prostate tumor cells, we first performed immunofluorescence 
assays to examine HIF-1α expression on an individual cell level. DU145, PC-3, and 
LNCaP cells were mock-infected or infected with MRV and incubated in normoxic or 
hypoxic conditions. At 24 h p.i., cells were fixed and stained with antibodies against HIF-
1α and the MRV non-structural protein µNS. In agreement with our data suggesting 
hypoxia does not negatively impact MRV replication (Fig. 3.1), viral factories, which are 
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key players in MRV replication and assembly, were not qualitatively different in size or 
number in infected cells grown in hypoxic and normoxic conditions (Fig. 3.2A).  
 
Figure 3.2. MRV infected hypoxic prostate tumor cells contain diminished HIF-1α  
protein levels. A) DU145, PC3, and LNCaP cells were mock-infected or infected with 
MRV T3D. 24 h p.i., cells were fixed, permeabilized, and immunostained with rabbit 
µNS antiserum (red) and mouse HIF-1α antibodies (green) followed by donkey α-rabbit 
Alexa 594- and donkey α-mouse Alexa 488-conjugated secondary antibodies. A merged 
image with DAPI is shown. Bar, 10 µm.  B) DU145, PC3 and LNCaP cells were mock-
infected or infected with MRV T3D and incubated under normoxic or hypoxic 
conditions. 4 h prior to infection, CoCl2 was added to cells where indicated.  At 24 h p.i., 
cells were harvested and proteins were separated on SDS-PAGE and transferred to 
nitrocellulose. Blots were immunostained with rabbit α-µNS antiserum, mouse α-HIF-1α 
antibodies, or rabbit α-β-actin antibodies followed by AP-conjugated goat α-rabbit or 
mouse secondary antibodies . C) DU145 cells were transfected with pHRE-HIF-1α. 24 h 
post-transfection, cells were mock-infected or infected with MRV T3D and incubated in 
normoxic or hypoxic conditions. At 12 or 24 h p.i., luciferase activity and total protein 
were measured. Relative amounts of luciferase per total protein are shown. Error bars 
represent SD of three independent experiments. Statistically significant differences 
(p<0.05) are marked with ‘*’. D) DU145 cells were mock-infected or infected with MRV 
T3D and incubated under normoxic or hypoxic conditions. 24 h p.i., total RNA was 
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isolated and measured using qPCR. Data from three independent experiments are 
represented as mean ± standard error of the mean (SEM). 
 
However, while uninfected hypoxic cells showed an increase in nuclear HIF-1α staining 
relative to normoxic cells, infected hypoxic cells did not show a similar increase in HIF-
1α staining in response to hypoxic incubation, suggesting MRV infection may prevent 
accumulation of HIF-1α protein under these conditions (Fig. 3.2A). We next performed 
immunoblot assays against HIF-1α in mock or MRV infected DU145, PC-3, and LNCaP 
cells grown in normoxic and hypoxic conditions. As expected, there was no accumulation 
of HIF-1α in mock- or MRV-infected samples grown in normoxic conditions (Fig. 3.2B, 
lanes 1 and 2 in each cell line), but abundant HIF-1α protein in hypoxic and CoCl2 
treated mock-infected samples (Fig. 3.2B, lanes 3 and 5 in each cell line). Strikingly, 
HIF-1α protein levels did not accumulate in MRV-infected hypoxic or CoCl2 treated 
cells (Fig. 3.2B, lanes 4 and 6 in each cell line) further suggesting MRV infection results 
in a strong downregulation of HIF-1α protein accumulation. To extend these findings, we 
examined whether HIF-1α protein activity was similarly diminished by MRV infection 
by measuring transcription from a HIF-1α-dependent firefly luciferase plasmid (pHRE-
HIF-1α) transfected into mock- and MRV-infected DU145 cells grown in normoxic and 
hypoxic conditions. These assays showed an expected increase in HIF-1α activity as 
measured by luciferase expression in uninfected hypoxic relative to normoxic cells. 
However, HIF-1α activity was strongly diminished in MRV-infected compared to mock-
infected hypoxic cells (Fig. 3.2C), further supporting the conclusion that MRV infection 
results in diminished levels of active HIF-1α protein in hypoxic prostate tumor cells. To 
rule out the possibility that MRV infection was interfering with HIF-1α mRNA levels, 
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we performed quantitative real time PCR on RNA isolated from mock- and MRV-
infected DU145 cells grown in normoxic and hypoxic environments. As shown in Fig. 
3.2D, there was no significant difference in HIF-1α mRNA levels in these samples. 
Altogether, these data strongly demonstrate that MRV infection interferes with 
accumulation of active HIF-1α protein in hypoxic prostate tumor cells.  
MRV induced downregulation of HIF-1α  occurs via ubiquitin-dependent 
proteasome-mediated degradation and translational inhibition. In uninfected cells 
under normoxic conditions, HIF-1α protein is rapidly targeted to the proteasome for 
degradation [19]. Thus we hypothesized that MRV induced HIF-1α downregulation in 
prostate tumor cells may require a functional proteasome. To test this, we examined HIF-
1α protein accumulation in the absence and presence of proteasome inhibitor, MG132. 
Mock and MRV infected DU145, PC-3, and LNCaP cells were grown in normoxic or 
hypoxic conditions and treated with MG132 for 4 h at either 8 or 20 h p.i., at which point 
cells were harvested and HIF-1α levels were measured by immunoblot.  MRV infection 
again resulted in decreased HIF-1α levels in hypoxic tumor cells in the absence of 
MG132 at both times p.i. in all cell lines (Fig 3.3A).  Addition of MG132 to the infected 
samples from 8-12 h p.i., was able to rescue HIF-1α to levels similar to those seen in 
uninfected cells (Fig. 3.3A); suggesting that MRV infection induces proteasome-
mediated degradation of HIF-1α in hypoxic prostate tumor cells at early times p.i.  
Surprisingly, the addition of MG132 at later times in infection was unable to rescue HIF-
1α, suggesting that, in addition to proteasome-mediated degradation, a second mode of 
inhibition of HIF-1α protein accumulation was occurring in MRV infected cells. Because  
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Figure 3.3. MRV induced downregulation of HIF-1α  occurs via ubiquitin-
dependent proteasome-mediated degradation and translational inhibition. A) 
DU145, PC3 and LNCaP cells were mock-infected or infected with MRV T3D and 
incubated under normoxic or hypoxic conditions. MG132 was added to cells at 8 or 20 h 
p.i. At 4 h following MG132 addition, cells were harvested and proteins were separated 
on SDS-PAGE and transferred to nitrocellulose. Blots were immunostained with rabbit 
α-µNS antiserum, mouse α-HIF-1α antibodies, or rabbit α-β-actin antibodies followed 
by AP-conjugated goat α-rabbit or mouse secondary antibodies. B) DU145 cells were 
mock-infected or infected with MRV T3D and incubated under normoxic or hypoxic 
conditions. L-AHA was added to the cells in methionine deficient media at 6 and 18 h p.i. 
Cells were harvested at 12 and 24 h p.i., and conjugated to biotin-alkyne via a Click-It 
reaction. Proteins were precipitated using streptavidin coated magnetic beads and 
separated on SDS-PAGE, transferred to nitrocellulose and immunostained with mouse α-
HIF-1α antibodies followed by AP-conjugated goat α- mouse secondary antibodies. C) 
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DU145 and PC3 cells were mock-infected or infected with MRV T3D and incubated 
under normoxic or hypoxic conditions. At 6 h p.i. F6 was added and cells were incubated 
an additional 6 h, at which point cells were harvested and proteins separated on SDS-
PAGE and transferred to nitrocellulose. Blots were immunostained with mouse α-HIF-
1α antibodies, rabbit α-β-actin antibodies and rabbit α-µNS antiserum followed by AP-
conjugated goat α-rabbit or mouse secondary antibodies. 
 
there was no difference in HIF-1α mRNA levels in uninfected and infected cells at this 
time p.i., (Fig. 3.2D), we hypothesized that MRV may inhibit HIF-1α mRNA translation.  
 To examine this, we directly measured the levels of HIF-1α protein translated at early 
and late times p.i.  Mock or MRV infected DU145 cells were incubated in normoxic and 
hypoxic conditions, and from 6-12 and 18-24 h p.i., the methionine analog, L-AHA was 
added to the cells to label proteins being translated during the incubation period. MG132  
was also added to some samples to prevent proteasome-mediated degradation of the 
labeled proteins. At 12 and 24 h respectively, cells were harvested and L-AHA labeled 
proteins were conjugated with biotin, and precipitated with streptavidin-conjugated 
beads, followed by HIF-1α immunoblot (Fig. 3.3B). In agreement with Fig. 3.3A, 
MG132 rescued the HIF-1α that was synthesized during the 6-12 h p.i. labeling period, 
confirming proteasome-mediated degradation of HIF-1α in infected cells during this 
time. However, MG132 treatment had little impact on accumulation of HIF-1α protein 
during the 18-24 h p.i. labeling time, suggesting that HIF-1α was not being synthesized 
during this period. Taken together, these data indicate that HIF-1α down-regulation in 
MRV infected hypoxic prostate tumor cells occurs via both proteasome-mediated 
degradation and inhibition of HIF-1α mRNA translation.  
HIF-1α is targeted to the proteasome through both ubiquitin-dependent and -
independent mechanisms [44]. To investigate whether MRV induced degradation of HIF-
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1α occurs through a ubiquitin-dependent or -independent pathway, we utilized a 
deubiquitinating enzyme inhibitor [NSC632839 hydrochloride (F6)] [45], which prevents 
removal of ubiquitin chains from polyubiquitinated proteins, inhibiting ubiquitin-
dependent, proteasome-mediated degradation. DU145 and PC-3 cells were mock or MRV 
infected and treated or not with F6 from 8-12 h p.i., at which point proteins were 
harvested, and HIF-1α levels were analyzed by immunoblot analysis. The addition of F6 
rescued HIF-1α from MRV-induced degradation (Fig. 3.3C) implicating a ubiquitin-
dependent pathway in MRV-induced HIF-1α proteasome-mediated degradation. 
 
 
Figure 3.4. PAS domain region of HIF-1α  is required for its MRV-induced down-
regulation.  PC-3 cells were transfected with pHA-HIF-1α, pHA-HIF-1α P402A/P564A 
or pHA-HIF-1α ΔPAS. At 24 h post-transfection cells were mock infected or infected 
with MRV T3D and incubated under normoxic or hypoxic conditions. At 12 h p.i., cells 
were harvested and proteins were separated on SDS-PAGE and transferred to 
nitrocellulose. Blots were immunostained with mouse α-HA antibodies, rabbit α-β-actin 
or rabbit α-µNS antiserum followed by AP-conjugated goat α-rabbit or mouse secondary 
antibodies. 
 
The PAS domains of HIF-1α  are required for MRV-induced degradation. Several 
regions within HIF-1α have been identified that are involved in proteasome-mediated 
degradation. Two of these regions (aa 380-417 and aa 556-572) contain prolines that 
when hydroxylated by PHD proteins results in recognition by the VHL E3 ubiquitin 
ligase and targeting of HIF-1α to the proteasome. Another region includes the PAS A and 
B domains (aa 85-158 and aa 228-298), which are competitively bound by either HSP90 
or RACK1 proteins, which promote stability or degradation of HIF-1α, respectively. To 
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determine if the MRV induced degradation of HIF-1α could be mapped to either of these 
regions within the HIF-1α protein, we utilized HA-tagged HIF-1α encoding plasmids 
that expressed wild-type HIF-1α (pHA-HIF-1α), PHD hydroxylation mutant HIF-1α 
(pHA-HIF-1α P402A/P564A) or a PAS A and B domain deletion mutant HIF-1α (pHA-
HIF-1α ΔPAS). PC-3 cells were transfected with wild-type or mutant plasmids, and at 24 
h post-transfection, cells were mock or MRV infected, and incubated under normoxic and 
hypoxic conditions. At 12 h p.i., cells were harvested, and accumulation of wild-type and 
mutant HA-HIF-1α proteins was determined by immunoblotting. In these experiments, 
MRV infection caused the downregulation of both wild-type HA-HIF-1α and mutant 
HA-HIF-1α−P402A/P564A) relative to mock infected cells. However the HA-HIF-1α  
ΔPAS protein accumulated to similar levels in both mock and MRV infected cells (Fig. 
3.4), suggesting that the PAS domains of HIF-1α are necessary for MRV infection 
induced degradation of HIF-1α.  
siRNA knockdown of RACK1 prevents MRV-induced degradation of HIF-1α . Since 
MRV infection induces degradation of HIF-1α under hypoxic conditions, and 
additionally induces the degradation of the VHL binding mutant HA-HIF-1α 
(P402A/P564A), it is unlikely that virus-induced degradation of HIF-1α occurs via the 
VHL-dependent pathway. However, deletion of the PAS domains of HIF-1α, which are 
necessary for RACK1 binding, prevents MRV-induced HIF-1α degradation (Fig. 3.4), 
suggesting that MRV induced degradation of HIF-1α may occur through a RACK1 
dependent pathway. To examine this possibility, we utilized two siRNAs (siRNA 1 and 
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siRNA 2) to knockdown RACK1 expression in mock and MRV infected normoxic and 
hypoxic tumor cells. Quantification of RACK1 levels following knockdown confirmed  
 
Figure 3.5. RACK1 knockdown by siRNAs prevents MRV-induced HIF-1α  
degradation in hypoxic tumor cells.  DU145 and PC-3 cells were transfected with 
control or RACK1-specific siRNAs. At 20 h post-transfection, cells were mock infected 
or infected with MRV T3D and incubated under normoxic or hypoxic conditions. At 12 h 
and 24 h p.i., cells were harvested and proteins were separated on SDS-PAGE and 
transferred to nitrocellulose. A) Blots were immunostained with rabbit α-µNS antiserum, 
mouse α-HIF-1α antibodies, mouse α-RACK1 monoclonal antibodies or rabbit α-β-actin 
antibodies followed by AP-conjugated goat α-rabbit or mouse secondary antibodies. B) 
Quantification of the RACK1 knockdown is represented in a bar graph. The data is the 
represented as the mean of all knockdown samples relative to the control and error bars 
represent the standard deviation. Statistically significant differences (p<0.05) are marked 
with ‘*’. 
 
that cells transfected with RACK1 siRNA 1 or 2 contained on average 60% less RACK1 
protein relative to control siRNA treated cells (Fig. 3.5B). As expected, MRV induced 
the downregulation of HIF-1α in control siRNA treated samples. In cells transfected with 
RACK1 siRNAs, at 12 h p.i., where we previously measured the greatest MRV impact on 
HIF-1α proteasome-mediated degradation, accumulation of HIF-1α was nearly 
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completely rescued (Fig. 3.5A). At 24 h p.i., there was also a substantial rescue of HIF-
1α in the MRV-infected RACK1 knockdown cells relative to control siRNA knockdown 
cells, however, complete rescue was not observed, likely as a result of the previously 
identified MRV-induced translational inhibition of HIF-1α mRNA by this time p.i. These 
results indicate that when RACK1 expression is diminished, MRV is unable to induce 
HIF-1α downregulation. Taken together with data in Fig. 3-4, this strongly suggests that 
MRV infection induces ubiquitin-dependent, proteasome-mediated degradation of HIF-
1α via a RACK1-dependent pathway in hypoxic prostate tumor cells.  
MRV infection induces apoptotic cell death in hypoxic prostate tumor cells. Hypoxic 
cancer cells evade apoptosis by upregulating anti-apoptotic factors [46-48] and 
downregulating pro-apoptotic factors [49], while MRV infection induces apoptosis [50]. 
To determine if MRV infection surmounts the hypoxic anti-apoptosis response in PCa 
cells, we performed a number of experiments. Viability assays based on live-cell protease 
activity showed that MRV infection caused significantly reduced viability of both 
hypoxic and normoxic tumor cells relative to uninfected cells (Fig. 3.6A). Concurrent 
apoptosis assays showed increased caspase 3/7 activity in MRV infected hypoxic and 
normoxic tumor cells when compared to uninfected cells (Fig. 3.6B), suggesting MRV 
was killing hypoxic tumor cells via an apoptotic pathway. Additional examination of 
uninfected and infected cell lysates showed cleaved PARP, a hallmark of apoptosis, in 
MRV infected hypoxic and normoxic tumor cells but not in uninfected cells (Fig. 3.6C).  
Apoptosis in cells occurs either via intrinsic and extrinsic pathways. The intrinsic 
pathway involves the activation of caspase 9 and the extrinsic pathway leads to caspase 8 
activation. MRV has been shown to induce apoptosis in normoxic cells in a tissue  
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Figure 3.6. MRV kills hypoxic prostate tumor cells via apoptosis. DU145 cells were 
mock-infected or infected with MRV T3D and incubated in normoxic or hypoxic 
conditions. A) At 0, 24 and 48 h p.i., cells were subjected to viability assay. B) At 0, 24, 
and 48 hours, cells were lysed and caspase 3/7 activity was measured. Error bars 
represent SD of three experimental replicates. Statistically significant differences 
(p<0.05) are marked with ‘*’. C) At 0, 24, and 48 hours, cells were lysed, and 
immunoblotted with antibodies against PARP. D) At 24 h p.i., cells were lysed and 
caspase 8 or caspase 9 activities was measured. Error bars represent SD of three 
experimental replicates. Statistically significant differences (p<0.05) are marked with ‘*’. 
 
specific manner and has been shown to be both caspase 8 and 9 dependent [51]. In order 
to further illuminate the mechanism of MRV induced apoptosis in hypoxic prostate tumor 
cells, we determined the activation status of caspase 8 and caspase 9 in MRV-infected 
hypoxic DU145 cells. Paclitaxel, which induces apoptosis via activation of both caspase 
8 and 9 was used as a positive control. Caspase activity was measured by Caspase 8/9 
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Glo assays at 24 and 48 h p.i. From these experiments, it was clear that MRV infection 
induced the activation of both caspases in normoxic and hypoxic prostate tumor cells 
(Fig. 3.6D).  Taken together, these data show that MRV infection has the capacity to 
override the anti-apoptotic effects of hypoxia and induce cell death by activating both the 
intrinsic and extrinsic apoptosis pathways, ultimately resulting in death of hypoxic 
prostate tumor cells. 
DISCUSSION  
 Low oxygen in prostate tumors is strongly predictive of relapse after 
therapy [52], illustrating the need to identify novel treatment strategies that target 
hypoxic tumor cells, and the HIF-1α protein that modulates the cellular hypoxic 
response. In this study, we have identified MRV as one such potential therapy by 
demonstrating that MRV replicates to high levels in prostate tumor cells grown in 
hypoxic environments (Fig. 1), induces massive downregulation of the HIF-1α protein 
via degradation and translational inhibition (Figs. 2, 3), and leads to apoptosis of the cells 
(Fig. 6). It is important to note that our data does not suggest that MRV specifically 
targets hypoxic cells, merely that the ability of MRV to replicate and induce apoptosis of 
tumor cells can be expanded to include those growing in a hypoxic microenvironment. 
These findings illustrate that the cellular adaptations that occur during hypoxia are not 
detrimental to successful MRV replication. This natural ability to replicate in hypoxic 
cells is similar to that seen in vesicular stomatitis virus (VSV), which has previously been 
shown to replicate in hypoxic HeLa cells and in hypoxic regions of C6 glioblastoma 
tumor xenograft [53]. Like VSV, the natural ability of MRV to replicate in hypoxic tumor 
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cells circumvents the need to alter the virus for specific replication in the hypoxic 
microenvironment, as is being investigated in other promising oncolytic viruses [53-55]. 
The downregulation of HIF-1α during MRV infection of PCa cells is mediated by 
proteasome-mediated degradation, and translational inhibition (Fig. 3). It remains unclear 
if HIF-1α degradation is a specific consequence of MRV infection, or occurs as a non-
specific result of MRV impact on other proteins involved in HIF-1α regulation. One 
particularly attractive candidate HIF-1α regulatory protein is HSP90, which has been 
shown to be involved in folding of the MRV trimeric attachment protein σ1 [56]. 
Usurpation of HSP90 in infected cells for σ1 folding may indirectly lead to RACK1-
mediated degradation of HIF-1α. Inhibition of HIF-1α translation at later times in MRV 
infection may occur as a result of modification of the translational machinery during 
virus infection. MRV has been shown to induce translational shutoff in many cell types, 
although we have been unable to detect a similar general inhibition of translation by 
MRV in the prostate tumor cells used in these studies (Gupta and Miller, unpublished). It 
is possible that sequestration of translation initiation factors by viral mRNA results in 
downregulation of HIF-1α translation. Further elucidation of how MRV infection 
modifies the cellular translation machinery should shed light on how HIF-1α mRNA 
translation is inhibited in infected cells.  
The PAS domain of HIF-1α, which is required for RACK1 and HSP90 binding 
[57], is required for MRV-induced degradation (Fig. 4). Additionally, siRNA knockdown 
of RACK1 inhibits MRV-induced HIF-1α degradation (Fig. 5). This suggests that MRV 
infection may result in modification of the interaction between RACK1 or HSP90 and 
HIF-1α. MRV infection may increase the RACK1/HIF-1α interaction or interfere with 
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the HSP90/HIF-1α interaction, leading to increased HIF-1α degradation. Moreover, post-
translational modifications of both HSP90 (acetylation) and RACK1 (phosphorylation) 
play important roles in regulation of HIF-1α association [58, 59] and it is possible that 
MRV infection alters these modifications. Finally, cellular modulators of interactions 
between HIF-1α, RACK1 and HSP90 that regulate HIF-1α protein levels may also be 
altered by MRV infection. Potential examples of this are the mammalian septin family 
member, SEPT9_v1, which has been reported to bind HIF-1α and prevent RACK1 
mediated proteasome targeting [60] or the SSAT2 protein, which binds to HIF-1α and 
RACK1 and promotes HIF-1α ubiquitination [61]. Elucidating these possibilities will be 
essential for gaining a full understanding of how MRV induces HIF-1α degradation and 
is currently under investigation. 
Hypoxia selects for cancer cells that can evade apoptosis [62]. We show that 
MRV can extend its oncolytic properties to hypoxic PCa cells via induction of apoptosis 
by activating both caspase 8 and 9 (Fig. 6). This suggests that MRV infection can 
override the anti-apoptotic pathways induced by hypoxia. Because HIF-1α plays a role in 
inhibition of apoptosis in hypoxic cells, it is possible that MRV-induced downregulation 
of HIF-1α allows cells to activate their normal apoptosis response to hypoxia in infected 
cells. The exact pathway of MRV-induced apoptosis in hypoxic prostate tumor cells is 
currently under investigation.  
We show that MRV downregulates the attractive cancer therapeutic target HIF-1α 
and induces apoptosis in hypoxic prostate tumor cells. These findings augment existing 
information regarding the capacity of MRV to infect different tumor cell types growing 
in diverse physiologically relevant microenvironments. Validation of MRV oncolytic 
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therapy of PCa in clinical trials is ongoing and has been shown to have a positive effect 
on disease regression [29]. MRV has also been shown to work in synergism with 
chemotherapy drugs such as docetaxel, which is the first line chemotherapy for treatment 
of androgen resistant PCa [30]. Our study extends the potential value of MRV treatment 
in PCa to include hypoxic prostate tumor cells, and provides a rationale to pursue future 
in vivo animal studies investigating the efficacy of MRV against hypoxic microregions 
within PCa tumors either alone or in combination with other standard chemotherapy 
treatments that are not effective against hypoxic cells. As hypoxia is present throughout 
the course of PCa, our data further suggests that MRV therapy may also be a strong 
candidate for targeting hypoxic cells and HIF-1α in PCa clinical trials. 
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ABSTRACT 
 Tumor outgrowth from the blood supply leads to low oxygen condition, or 
hypoxia in microregions of solid tumors. The transcription factor, Hypoxia Inducible 
Factor-1 (HIF-1), regulates these hypoxic cells, and is formed when one of its 
components, HIF-1α, is stabilized. We previously found that Mammalian Orthoreovirus 
(MRV), a potent oncolytic virus, causes the downregulation of HIF-1α in infected 
hypoxic cells.  Here we report that MRV proteins, µ1 and µ2 induce the downregulation 
of HIF-1α independent of viral infection. The ability of µ2 to downregulate HIF-1α was 
attributed to strain specific differences, where the T1L and T3DC strains induced more 
downregulation than the T3DF strain. By examining single amino-acid and deletion 
mutants, the region containing aa 188-380, and specifically amino-acid 208 of µ2, 
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and φ domain of µ1 were determined to be necessary for HIF-1α downregulation. These 
observations provide new insights into the effects of specific MRV proteins on HIF-1α 
when expressed in hypoxic cells.  
INTRODUCTION 
 Mammalian Orthoreovirus (MRV), a non-enveloped, double stranded RNA virus 
is a member of the family Reoviridae. MRV infects all mammals including humans, but 
is generally non-pathogenic [1]. Three reovirus serotypes have been recognized based on 
neutralization and hemagglutination profiles; type 1 Lang (T1L), type 2 Jones (T2J), and 
type 3 Dearing (T3D) [2-4]. The MRV genome approximates 23.5 kilobases (Kb) and 
consists of 10 RNA segments, categorized into 3 large (L1, L2 and L3), 3 medium (M1, 
M2 and M3) and 4 small (S1, S2, S3 and S4) segments based on size. These segments are 
primarily mono-cistronic, and encode for eight structural 
(λ1, λ2, λ3, µ1, µ2, σ1, σ2 and σ3) and four non-structural (µNS, µNSC, σ1s and σNS) 
proteins.  MRV particles comprise the ten-segment dsRNA genome surrounded by two 
concentric icosahedral capsids.  The innermost capsid, which is a self-contained 
transcriptase unit, is known as the core. The core is surrounded by an outer capsid made 
up of proteins that play important roles in virus entry. 
 The large segments (L1, L2 and L3) encode for structural proteins λ3, λ2 and λ1 
respectively. The λ3 protein is a minor inner capsid protein and is the catalytic subunit of 
the viral RNA-dependent RNA polymerase [5]. λ2 is a core spike protein, which forms 
pentameric turrets through which the viral mRNAs move during transcription	  [6-8] and is 
also responsible for adding the 5’ methylated cap structure to viral mRNAs during their 
synthesis [9].  λ1, a minor inner capsid protein has been implicated as an RNA helicase 
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and as being responsible for the removal of the terminal phosphate from newly 
synthesized mRNA in preparation for capping [10].  
The M1-encoded protein, µ2, has been shown to have RNA-binding, nucleoside-
triphosphatase (NTPase) and RNA 5'-triphosphatase (RTPase) activities and thus is 
thought to play an important polymerase co-factor role in viral mRNA synthesis [11-13]. 
µ2 is also a microtubule-associated protein, an interaction that appears to be important for 
the morphological structure (globular or filamentous) of MRV replication factories (see 
below) and in hyper-acetylation of cellular tubulin. [14]. µ2 was also recently shown to 
contain an immunoreceptor tyrosine-based activation motif (ITAM) that impacts virus-
induced apoptosis and spread in a cell type specific manner	   [15]. The M2-encoded µ1 
protein is an outer capsid protein that plays a key membrane penetration role in virus 
entry. Autolytic cleavage of µ1 divides it into myristoylated µ1N and µ1C that are further 
cleaved to δ and φ fragments [16-18].  Evidence suggests that myristoylated µ1N inserts 
and pokes holes in the endosomal membrane to release viral core particles into the 
cytoplasm [19-22]. µ1 also plays a critical role in apoptosis induction by MRV [23-26]. 
Residues 582-611 of the φ domain of the protein localize to the mitochondrial membranes 
and appear to be both necessary and sufficient for inducing apoptosis [25].  The 
nonstructural µNS protein plays a principal role during infection in forming the structural 
matrix of phase-dense regions that form in MRV infected cells that are termed viral 
factories (VFs) and which appear to be the location of virus RNA transcription, 
translation, replication and particle assembly [27-29]. VFs contain dsRNAs, cores and 
fully assembled capsids, and all of the viral-encoded proteins, many of which are 
recruited to the VFs via an association with the µNS N-terminus [29-31]. Either the 
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formation of the VF structure by µNS, the recruitment of viral proteins and cores to the 
VF by µNS, or both is required for successful virus infection, as siRNA knockdown of 
the M3 mRNA leads to a massive decrease in virus titer [32]. 
The small genome segments (S1, S2, S3, and S4) encode σ1, σ2, σNS, and σ3 
respectively. σ1 is the virus attachment protein [33, 34], which binds to the primary 
receptor junction adhesion molecule (JAM-A) and secondary receptor sialic acid (SA) 
[35, 36]. σ2 is a major, inner capsid protein that has been predicted to bind weakly to 
dsRNA [37]. The non-structural protein σNS has non-specific RNA-binding ability with 
a strong affinity for single-stranded RNA	   [38, 39], and a non-canonical, ATP-
independent helicase activity [40].  It has also recently been found to associate with 43S 
preinitiation complexes at VF margins and may have some role in translation of viral 
mRNA [41]. S4 encodes for the major outer capsid protein σ3, which forms a protective 
cap for the membrane penetration protein µ1 that is removed during entry to allow for 
penetration of the core particle into the cytoplasm [42, 43]. σ3 also has a dsRNA binding 
property that is thought to counteract the dsRNA dependent protein kinase PKR, which is 
induced as an antiviral defense mechanism by the host cell [39, 44-47].  
 MRV is an oncolytic virus that replicates preferentially in cancer cells over 
normal cells [48]. MRV oncolytic activity has been demonstrated to be an effective 
therapy in animal models against many cancer types [49-51]. The preclinical success in 
animal models led to its development and clinical testing as a cancer therapy in a number 
of Phase I/II/III human clinical trials. It has proved to be a nontoxic and efficient therapy 
for many different cancer types leading to disease stabilization and tumor regression in 
many patients [52-57]. 
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 Hypoxia is a condition of low oxygen and a common feature of solid tumors. In 
cancer, hypoxia develops as a result of the loss of angiogenesis to rapidly dividing tumor 
cells, leading to decreases in cell oxygenation. Hypoxic tumor cells are known to be 
resistant to chemotherapy and radiation therapy and are strongly associated with disease 
progression and metastasis [58, 59]. Hypoxic cells survive due to the regulatory action of 
the transcription factor, Hypoxia Inducible Factor 1 (HIF-1), which upregulates genes 
required for growth and survival [60]. HIF-1 is a heterodimer of two proteins, HIF-1α 
and HIF-1β. While HIF-1β is constitutively expressed, the formation of HIF-1 is 
dependent on the availability of HIF-1α, which is tightly regulated post-translationally 
via oxygen dependent and independent degradation pathways [61]. HIF-1 binds to 
specific DNA sequence, called the hypoxia response element (HRE), in the promoter or 
enhancer regions of genes it regulates [62]. 
 We recently demonstrated that MRV is successful in inducing apoptosis in 
normoxic and hypoxic prostate cancer cells. In addition, we showed that MRV induces a 
massive downregulation of HIF-1α in hypoxic prostate tumor cells via proteasome 
mediated degradation and translational inhibition. HIF-1α degradation was found to be 
dependent on the receptor for activated C kinase I (RACK1) protein [63]. As MRV 
infection induces a number of changes in the cell as a result of host response 
mechanisms, it was not clear if this downregulation occurred as a result of direct or 
indirect involvement of individual MRV proteins or an indirect effect of MRV infection 
in the cell impacting some other HIF-1α regulatory protein. In this study we set out to 
answer this question by measuring HIF-1α stability in cells expressing a subset of MRV 
proteins.  
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MATERIALS AND METHODS 
Cells and reagents BHK-21 cells were maintained in DMEM (Sigma) containing 10% 
fetal bovine serum (Atlanta Biologicals), penicillin-streptomycin (100 IU/ml, Mediatech), 
L-Glutamine (2nM, Mediatech) and 1% Non-Essential Amino acids (Invitrogen). 
Primary antibodies used were as follows: mouse monoclonal anti-HIF-1α (catalog # 
610958), mouse polyclonal anti-α-tubulin (catalog #T6074, Sigma), rabbit polyclonal 
anti-µNS [64], rabbit polyclonal anti-µ2	   [28], rabbit polyclonal anti-σNS	   [65], rabbit 
polyclonal anti-λ1	  [66], and mouse monoclonal anti-µ1 (4A3)	  [67]. Secondary antibodies 
used for immunoblot experiments were alkaline phosphatase (AP)-conjugated goat anti-
mouse (catalog #1706520) or anti-rabbit IgG (catalog #170-6518, Bio-Rad).  
Hypoxia	  Hypoxic conditions were obtained by incubating cells in 1% O2 and 5% CO2 at 
37°C in a Galaxy 48R CO2 Incubator (New Brunswick Scientific) equipped with 1-19% 
O2 controls. All cells were adapted to hypoxia for 4 h prior to infection or transfection. 
Immunoblotting Cells were lysed in 100 µL 2X SDS protein loading buffer (125 mM 
Tris HCl [pH 6.8], 200 mM DTT, 4% SDS, 0.2% Bromophenol blue, 20% Glycerol). 
Immunoblots were performed as previously described [68]. Blots were exposed to Lumi-
PhosTM WB Chemiluminescent Substrate (Thermo Scientific), and images were collected 
and quantified using a ChemiDoc XRS camera and QuantityOne software (Bio-Rad). All 
experiments were independently performed at least 3 times and representative results are 
shown. 
Plasmid Construction pCI-M3(T1L) [28], pCI-S3(T1L), pCI-M1(T1L), pCI-M1(T3DC), 
pCI-Μ1(T3DF) and pCI-Μ1(T1L)-P208S [14], pCI-L3(T1L) and pHRE-HIF-1α [63], 
pHA-HIF-1α [Addgene plasmid 18949, [69]], pCI-M2, pCI-M2(43-708), pCI-M2(43-
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582) and pCI-M2(1-582) [25]  were previously described.  pCI-M1(T3DF)-S208P (as 
described in [14]) and pCI-M1(T3DC)-K415A/K419A were created by overlap PCR 
using internal primers containing respective nucleotide mutations and end primers 
containing XmaI and XhoI restriction sites. Following PCR and digestion with XmaI and 
XhoI, the fragment was ligated into the XmaI/XhoI digested pCI-neo plasmid. µ2 
deletion mutants (pCI-M1-T3DC(1-188), pCI-M1-T3DC(1-380), pCI-M1-T3DC(1-559) 
and pCI-M1-T3DC(181-736)) were constructed by amplifying the desired µ2 regions with 
primers containing XbaI and XhoI restriction sites using pCI- M1(T3DC) as template. 
The PCR products were ligated into an Xba1/XhoI digested pCI-neo vector plasmid. 
Following transformation, and screening, all plasmids were verified by sequencing.  
Transfection Plasmid transfections were performed using TransIT-LT1 (Mirus) 
transfection reagent as per manufacturer’s protocol. Transfected samples were incubated 
for 24 h before lysate collection. 
Luciferase Assay Cells were transfected with pHRE-HIF-1α using Lipofectamine 2000 
(Invitrogen) and indicated MRV protein expression plasmids according to the supplier’s 
protocol. Luciferase expression was measured using the One-Glo Luciferase Assay Kit 
and the luminescence function of a GloMax Multi+ microplate reader (Promega). 
Following recording of luminescence, cells were lysed and total protein was measured 
using Bradford Assay (Biorad) and the absorbance function of a GloMax Multi+ 
microplate reader. Luminescence levels were normalized to total protein and plotted on a 
graph. Results shown are means and standard error of three experimental replicates. The 
statistical significance was calculated using the average of 3 experimental replicates. 
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Statistical Analysis Statistical significance was determined using student’s t-test and 
two-tailed p value calculated with GraphPad software. Differences in groups for which 
p<0.05 were considered to be statistically significant and are indicated with an asterisk in 
figures. 
RESULTS 
MRV proteins µ1 and µ2 independently induce downregulation of HIF-1α  We 
recently demonstrated that MRV infection results in HIF-1α downregulation by 12 h p.i. 
via a ubiquitin-mediated, proteasome-dependent pathway. Moreover, we showed that by 
24 h p.i., MRV infection also induced translational inhibition of HIF-1α. We postulated 
that HIF-1α degradation and/or translational inhibition during MRV infection may be due 
to the action of individual MRV proteins, or alternatively, may occur indirectly as a result 
of the host cell response to infection. To begin to investigate the mechanism of HIF-1α 
downregulation in MRV infected cells, we examined the impact of expression of 
individual MRV proteins on HIF-1α accumulation in transfected cells. BHK-21 cells 
were transfected with plasmids expressing human HIF-1α and individual MRV proteins. 
24 h post transfection, cells were harvested and lysates were subjected to immunoblot 
analysis using antibodies against HIF-1α and individual MRV proteins. In initial 
experiments, transfections were performed using plasmids expressing each of the 10 
major MRV proteins (λ1, λ2, λ3, µ1, µ2, µNS, σ1, σ2, σNS, and σ3). However, we had 
difficulty detecting 5 of these proteins (λ2, λ3, σ1, σ2 and σ3) by immunoblot using our 
lab and other commercially available antibodies for reasons that are currently unclear, 
therefore, while we saw no impact of transfection of plasmids predicted to express these 
proteins on HIF-1α accumulation, we cannot confirm they were expressed in cells, and  




Figure 4.1. MRV proteins µ1 and µ2 induce downregulation of HIF-
1α  independent of infection. BHK-21 cells were transfected with pCI-M3(T1L), pCI-
S3(T1L), pCI-M1(T1L), pCI-M2(T1L), and pCI-L3(T1L) along with pHA-HIF-1α. At 
24 h p.t., cells were harvested and proteins were separated on SDS-PAGE and transferred 
to nitrocellulose. Blots were immunostained with rabbit anti-µNS, rabbit anti-µ2, rabbit 
anti-σNS, rabbit anti-λ1, mouse anti-µ1 (4A3), mouse anti-HIF-1α, or mouse α-α-
tubulin antibodies followed by AP-conjugated goat α-rabbit or mouse secondary 
antibodies. 
 
must exclude them from this study. We were able to demonstrate expression of the 
remaining 5 MRV proteins (λ1, µ1, µ2, µNS, and σNS) in these experiments and found 
that while expression of λ1, µNS, and σNS had no obvious effect on HIF-1α 
accumulation in hypoxic cells, individual expression of µ1 and µ2 induced a clear 
downregulation of HIF-1α protein accumulation under hypoxic conditions (Fig. 4.1 A 
and B). These findings demonstrate that two individual MRV proteins have the capacity 
to modulate HIF-1α expression during hypoxia.   
Amino acid 208 of µ2 plays a partial role in HIF-1α  downregulation. Parker et al., 
showed that there was a strain-dependent difference in MRV VF morphology that 
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mapped to the M1 gene encoding µ2 [14]. Using several strains, including the prototypic 
T1L strain, a T3D strain whose lineage was through the Bernie Fields lab (termed 
variously T3DF or T3DN), and a T3D strain whose lineage was through the Bill 
Cashdollar lab (termed T3DC), it was shown that cells infected with T1L and T3DC 
contained VFs with a filamentous morphology, while T3DF infected cells contained VFs 
with a globular morphology. Subsequent studies have highlighted a number of other 
phenotypic differences between these strains that also map to µ2 [70-72]. To examine if 
there were phenotypic differences in HIF-1α accumulation between µ2 proteins derived 
from T1L, T3DC, or T3DF, we co-transfected cells with plasmids expressing HIF-1α and 
each of the three µ2 proteins. At 24 h p.t., cells were harvested and lysates were separated 
on SDS-PAGE and immunoblotted with HIF-1α and µ2 antibodies. In these experiments, 
while there was clear downregulation of HIF-1α in cells expressing each of the three µ2 
proteins, there was a noticeable increase in HIF-1α downregulation in µ2-T1L and µ2-
T3DC expressing cells relative to µ2-T3DF expressing cells (Fig. 4.2A). To confirm these 
findings, we additionally examined HIF-1α activity in µ2 expressing cells by 
cotransfecting BHK-21 cells with plasmids encoding each µ2 protein with a plasmid 
vector that expresses luciferase in a HIF response element (HRE)-dependent manner. 
Luciferase levels measured at 24 h p.t., clearly support the immunoblot results with all 
three of the µ2 proteins inducing downregulation of HIF-1α activity relative to control 
plasmid alone, and T3DF µ2 inducing less downregulation of HIF-1α activity when 
compared to T1L and T3DC (Fig. 4.2D). The difference between µ2-T3DC and µ2-T3DF 
was significant, whereas the p-value for µ2-T1L and µ2-T3DF was 0.058. 
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Differences in VF morphology and other phenotypes have been attributed to the 
amino acid at the 208th position of µ2, which is a proline in T1L and T3DC, but a serine  
 
 
Figure 4.2. Involvement of previously described functional properties of µ2 in HIF-
1α  downregulation A) BHK-21 cells were transfected with pCI-M1(T1L), pCI-
M1(T3DC) and pCI-Μ1(T3DF) along with pHA-HIF-1α. At 24 h p.t., cells were 
harvested and proteins were separated on SDS-PAGE and transferred to nitrocellulose. 
Blots were immunostained with rabbit anti-µ2, mouse anti-HIF-1α, or mouse α-α-tubulin 
antibodies followed by AP-conjugated goat α-rabbit or mouse secondary antibodies. B) 
BHK-21 cells were transfected with pCI-M1(T1L), pCI-M1(T3DC), pCI-Μ1(T3DF), pCI-
M1-T1L(P208S) and  pCI-M1-T3DF(S208P) along with pHA-HIF-1α. At 24 h p.t., cells 
were harvested and proteins were separated on SDS-PAGE and transferred to 
nitrocellulose. Blots were immunostained with rabbit anti-µ2, mouse anti-HIF-1α, or 
mouse α-α-tubulin antibodies followed by AP-conjugated goat α-rabbit or mouse 
secondary antibodies. C) BHK-21 cells were transfected with pCI-M1(T1L), pCI-
M1(T3DC), pCI-Μ1(T3DF) and pCI-M1-T3DC(K415A/K419A) along with pHA-HIF-1α. 
At 24 h p.t., cells were harvested and proteins were separated on SDS-PAGE and 
transferred to nitrocellulose. Blots were immunostained with rabbit anti-µ2, mouse anti-
HIF-1α, or mouse α-α-tubulin antibodies followed by AP-conjugated goat α-rabbit or 
mouse secondary antibodies. D) BHK-21 cells were transfected with pCI-M1(T1L), pCI-
M1(T3DC), pCI-Μ1(T3DF), pCI-M1-T1L(P208S), pCI-M1-T3DF(S208P) and pCI-M1-
T3DC(K415A/K419A) along with pHRE-HIF-1α and incubated under hypoxic coditions. 
At 24h p.t., luciferase activity and total protein were measured. Relative amounts of 
luciferase per total protein are shown. Error bars represent SE of three independent 
experiments. Statistically significant differences (p<0.05) are marked with ‘*’. 
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in T3DF. This single amino-acid was also implicated in hyper-acetylation of tubulin in 
MRV infected cells, where T1L and T3DC caused hyper-acetylation of tubulin and T3DF 
did not [14]. In our experiments, T3DF µ2 expression induced less downregulation of 
HIF-1α than either T1L or T3DC µ2 (Fig. 4.2B) and thus we were interested to determine 
if the proline to serine amino acid change in µ2 had any effect on HIF-1α 
downregulation. To examine this, BHK-21 cells were co-transfected with plasmids 
encoding either µ2-T1L, µ2-T3DC, µ2-T3DF, µ2-T1L(P208S) or µ2-T3DF(S208P) and 
HIF-1α and at 24 h p.t., HIF-1α levels were examined by immunoblot. We observed that 
changing the proline at 208 of µ2-T1L to serine (µ2-T1L(P208S)) resulted in less 
downregulation of HIF-1α as compared to wt µ2-T1L (Fig 4.2B). Similarly, changing the 
serine to proline in µ2-T3DF (µ2-T3DF(S208P)) resulted in increased downregulation 
relative to wt T3DF µ2. To confirm these findings, we also examined HIF-1α activity in 
cells expressing µ2-T3DF (P208S) and µ2-T1L (S208P) relative to their parental proteins. 
Supporting our immunoblot data, HIF-1α activity was significantly lower when the 
proline at position 208 of µ2-T3DF was changed to serine, and higher when the serine at 
position 208 of T1L was changed to proline (p-value <0.05). Thus this data confirmed 
that the amino-acid difference at position 208 in MRV µ2 appears to have partial impact 
on the capacity of µ2 to downregulate HIF-1α, although it does not appear to be the sole 
factor impacting µ2 modulation of HIF-1α.  
NTPase activity of µ2 is not involved in HIF-1α  downregulation. µ2 has been shown 
to have NTPase activity, and mutation of K419 and K415 to alanine within µ2 was 
sufficient to eliminate this activity [12, 13]. Therefore, we examined if the NTPase 
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activity of µ2 is necessary for HIF-1α downregulation. In order to test our hypothesis we 
constructed mutations in µ2-T3DC to generate µ2-T3DC(K415A/K419A). The mutated 
µ2 was expressed individually with HIF-1α and subjected to immunoblot analysis using 
µ2 and HIF-1α antibodies. No noticeable difference was observed in the downregulation 
of HIF-1α by wt µ2-T3DC when compared to µ2-T3DC(K415A/K419A) (Fig 4.2C). To 
further verify our results, we examined HIF-1α activity by measuring transcription from 
the HIF-1α-dependent firefly luciferase plasmid in cells transfected with a plasmid 
expressing µ2-T3DC(K415A/K419A) protein. We observed results similar to what was 
measured by immunoblot (Fig 4.2D), suggesting the µ2 NTPase activity does not play a 
role in HIF-1α downregulation in hypoxic cells. 
Region 188-380 of µ2 is necessary for HIF-1α  downregulation While our prior results 
suggested that amino-acid 208 plays some role in µ2 downregulation of HIF-1α, 
mutations of this amino-acid did not fully restore HIF-1α protein accumulation or 
activity in cells expressing T3DF µ2, nor did they fully disrupt T1L µ2 downregulation of 
HIF-1α protein accumulation or activity. In order to identify a region of µ2 required to 
induce wt levels of HIF-1α downregulation, we created deletion mutants of µ2-T3DC 
(Fig 4.3A).  Deletion mutants from both 5' and 3' ends were made, although two of these 
mutants [µ2-T3DC(380-736) and µ2-T3DC(559-736)] were undetectable by immunoblot 
following transfection so we excluded them from this study. For all of the remaining 
mutants, we observed multiple fragments that were detected by the µ2 antibody along 
with the predicted truncated proteins (Fig 4.2B). The presence of two µ2 fragments has 
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been previously noted in the T3D strain, although it is unclear at this time if the multiple 
fragments observed in our mutants were derived from the same mechanism as those  
 
Figure 4.3.  Regions of µ2 necessary for HIF-1α  downregulation. A) Schematic 
representation of µ2 deletion mutants. B) BHK-21 cells were transfected with pCI-
M1(T3DC) pCI-M1-T3DC(1-188), pCI-M1-T3DC(1-380), pCI-M1-T3DC(1-559) and pCI-
M1-T3DC(181-736) along with pHA-HIF-1α. At 24 h p.t., cells were harvested and 
proteins were separated on SDS-PAGE and transferred to nitrocellulose. Blots were 
immunostained with rabbit anti-µ2, mouse anti-HIF-1α, or mouse α-α-tubulin antibodies 
followed by AP-conjugated goat α-rabbit or mouse secondary antibodies. 
 
previously described [71, 74]. Plasmids expressing the deletion mutants of µ2-T3DC were 
transfected along with the HIF-1α plasmid into BHK-21 cells and analyzed for HIF-1α 
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protein levels. We observed that while µ2-T3DC(1-380), µ2-T3DC(1-559) and µ2-
T3DC(181-736) caused HIF-1α downregulation to varying levels, µ2-T3DC(1-188) was 
unable to do so (Fig 4.3B). While the µ2-T3DC(181-736) mutant only partially 
downregulated HIF-1α, the µ2-T3DC(1-380) and µ2-T3DC(1-559) seemed to fully 
downregulate the protein. Taken together, these results suggest that the carboxyl terminal 
177 amino-acids of µ2 are dispensable for HIF-1α degradation. Further, while amino-
acids 1-180 are unable to induce downregulation of HIF-1α independently, it appears 
they may contribute to the downregulation as the mutants that contain this amino (N)-
terminal region, (1-380, 1-559) induce greater downregulation of HIF-1α than the mutant 
that does not contain this region (181-736). Interestingly, all of the truncation mutants 
that showed some HIF-1α downregulation contain amino-acid 208, which was shown 
above to have partial impact on HIF-1α downregulation.  
The φ  domain of µ1 is required for HIF-1α  downregulation. The µ1 protein is 
divided into three regions by proteolytic cleavage sites: the N-terminal, myristoylated 
fragment µ1N (aa 2 to 41); the center fragment δ (aa 42 to 582); and the C-terminal 
fragment φ (aa 582 to 708) [75] (Fig 4.4A). Plasmids with different combinations of 
deletions, as shown in Figure 4A, were previously described [25].  To determine the 
regions of µ1 necessary for HIF-1α downregulation, plasmids encoding µ1-T1L, µ1-
T1L(43-708), µ1-T1L(1-582) and µ1-T1L(43-582) were transfected with a plasmid  
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Figure 4.4.  The φ  domain of µ1 is required for HIF-1α  downregulation. A) 
Schematic representation of µ1 deletion mutants. B) BHK-21 cells were transfected with 
pCI-M2-T1L, pCI-M2-T1L, pCI-M2-T1L(43-708), pCI-M2-T1L(1-582) and pCI-M2-
T1L(43-582) along with pHA-HIF-1α. At 24 h p.t., cells were harvested and proteins 
were separated on SDS-PAGE and transferred to nitrocellulose. Blots were 
immunostained with mouse anti-HIF-1α, mouse anti-µ1 (4A3), or mouse α-α-tubulin 
antibodies followed by AP-conjugated goat α-rabbit or mouse secondary antibodies. C) 
BHK-21 cells were transfected with pCI-M2-T1L, pCI-M2-T1L, pCI-M2-T1L(43-708), 
pCI-M2-T1L(1-582) and pCI-M2-T1L(43-582) along with pHRE-HIF-1α 
and incubated under hypoxic coditions. At 24h p.t., luciferase activity and total protein 
were measured. Relative amounts of luciferase per total protein are shown. Error bars 
represent SE of three independent experiments. Statistically significant differences 
(p<0.05) are marked with ‘*’. 
 
encoding HIF-1α into BHK-21 cells and following 24 h incubation, analyzed by 
immunoblot. µ1-T1L(1-582) and µ1-T1L(43-582), both of which have the φ region 
deleted, failed to cause downregulation of HIF-1α, whereas µ1-T1L(43-708) maintained 
HIF-1α downregulation (Fig 4.4B), suggesting that the φ region (582-708) was necessary 
for HIF-1α downregulation. To verify these results, we again tested HIF-1α activity by 
luciferase assay, transfecting BHK-21 cells with pHRE-HIF-1α and each of the wt and 
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µ1 mutants and incubating under hypoxic conditions for 24 h. Similar to results observed 
in Figure 4B, these results showed that µ1-T1L(43-708) induced a similar decrease in 
HIF-1α activity to wildtype µ1, whereas HIF-1α activity was significantly increased in 
samples transfected with µ1-T1L(1-582) and µ1-T1L(43-582) when compared to wt µ1 
(Fig 4.4C).  Thus taken together, these results strongly suggest that the φ region of µ1 is 
necessary for downregulation of HIF-1α protein levels and activity. 
DISCUSSION 
Hypoxia adaptation is accompanied by the upregulation of genes responsible for 
cancer proliferation, apoptosis resistance, and angiogenesis [76, 77]. These in turn lead to 
increased tumor invasion and metastasis, which results in poor clinical outcome [78, 79]. 
For these reasons, hypoxia in tumor always leads to poor prognosis. The interaction of 
hypoxic microenvironment and oncolytic viruses is important for effective viral 
replication and subsequent oncolysis and therefore in determining the success of 
oncolytic virotherapy overall. We had previously reported that MRV infection, in 
hypoxic cells, caused the downregulation of HIF-1α, and therefore MRV as an oncolytic 
virus offers additional benefits by targeting hypoxic cells.  This is in contrast to some 
other viruses, for example Hepatitis C Virus (HCV), which not only cause cancer, but 
also result in the stabilization of HIF-1α [74].  In this study we report that MRV proteins 
µ1 and µ2 can induce the downregulation of HIF-1α when expressed individually. This 
again, is in contrast to a few other viral proteins, such as the latent membrane protein 1 
(LMP1) of the oncogenic Epstein-Barr Virus (EBV) [80] and viral IFN regulatory factor 
3 (vIRF3) of the Kaposi’s sarcoma-associated herpesvirus (KSHV) [81], which stabilize 
 113  
HIF-1α and thus add to their oncogenic properties.  Therefore, the oncolytic virotherapy 
of MRV proves to be very effective where hypoxic microenvironment is concerned. 
 µ2 from T1L and T3DC, but not T3DF has previously been found to induce 
hyperacetylation of microtubules [14]. Hyperacetylation of tubulin can be caused either 
by increased activation of the acetylase or inhibition of the deacetylase involved in 
regulation of tubulin acetylation. The deacetylase for tubulin is a member of the histone 
deacetylase family member, HDAC6 [82]. HDAC6 is also responsible for deactylation of 
the chaperone protein, heat shock protein 90 (HSP90) [83]. Interestingly, HSP90 
acetylation modulates HSP90 association with HIF-1α [84]. HSP90 competes with the 
cellular RACK1 protein for binding to HIF-1α Per-Arnt-Sim (PAS) domain [85]. When 
HSP90 is not acetylated, it can bind and stabilize HIF-1α and prevent RACK1 binding. 
When HSP90 is acetylated, it can no longer bind HIF-1α, and the RACK1 protein binds 
the PAS domain and targets HIF-1α for proteasome-mediated degradation [84, 86]. 
Therefore, if the previously described increase in tubulin acetylation induced by µ2 
occurs through inhibition of HDAC6 this may also lead to hyperacetylation of other 
HDAC6 regulated proteins, including HSP90. If this were the case, it would also explain 
the differences we observed in HIF-1α downregulation between µ2 encoded by different 
MRV strains, and differences in µ2 amino-acid 208, which mirrored differences 
previously described in tubulin acetylation. We made several attempts to detect 
acetylated HSP90 in infected and even HDAC inhibitor treated samples, but were 
unsuccessful. Consequently we were unable to verify this hypothesis.  
 The φ region of µ1 was found to be required for HIF-1α downregulation. This 
region has been shown to be sufficient to induce apoptosis [23, 25]. It is possible that the 
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apoptosis induction pathway activated by µ1 exhibits crosstalk with a HIF-1α regulatory 
pathway and consequently causes downregulation of HIF-1α. Further investigation is 
needed to identify and better understand the involved pathways. This may potentially 
shed light on a novel function of the µ1 protein, and also uncover unknown HIF-1α 
regulation processes. The dual ability of µ1 to induce apoptosis and HIF-1α 
downregulation may indicate µ1 should be examined as a potential candidate for gene 
therapies targeting tumor cells. 
 Future studies are needed to completely understand the role µ1 and µ2 are playing 
in the downregulation of HIF-1α in context of infection. It is possible that when 
expressed independently of infection that these proteins behave differently than they do 
in infected cells. For example, µ1 associates strongly with σ3 in infected cells [87-89], 
and may behave differently in the presence of σ3. Unfortunately, we were unable to 
examine the impact of σ3 expression on µ1 downregulation of HIF-1α due to the lack of 
a functioning σ3 antibody. Despite these limitations, the novel findings in this study are 
interesting and lay the basis for further research that may help in a better understanding 
of MRV protein-host protein interactions and function of the MRV proteins.  
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Background: Growth of prostate cancer (PCa) is dependent on androgens, thus making 
androgen ablation an effective therapy. Relapse and mortality occurs when the cancer 
progresses to androgen independent growth. Hypoxia, a microenvironment of low oxygen 
found in most prostate tumors, acts as a protective shield against cell death by regulating 
alternate and more aggressive pathways of growth. Hypoxia-regulated proteins are 
induced during androgen ablation therapy and lead to the selection of aggressive and 
metastatic androgen independent cells. Therapies targeting hypoxic and androgen 
dependent cells, which may prevent progression to androgen independence, are critically 
needed. Oncolytic Mammalian Orthoreovirus (MRV) has shown considerable promise 
for the treatment of prostate tumors in animal studies and clinical trials. 
Method: A number of key proteins were investigated to determine the impact of 
oncolytic MRV infection on their production and activity in normoxic and hypoxic 
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androgen-dependent tumor cells. Phosphorylated Akt (P-Akt), Androgen Receptor (AR) 
and Prostate Specific Antigen (PSA) protein levels were examined by immunoblot 
analysis.  AR activity was measured using ARE driven luciferase expression and by PSA 
protein abundance and secretion as measured by immunoblot and ELISA. AR mRNA 
levels were quantified using qPCR assay. Cell viability and caspase assays were also 
performed to determine the impact of MRV on cell death and apoptosis of these cells. 
Results: Infection of hypoxic and normoxic androgen-dependent LNCaP cells with MRV 
induced apoptosis and cell death. MRV infection additionally resulted in downregulation 
of P-Akt, and decreased accumulation of AR mRNA, AR protein, and cellular and 
secreted PSA under both normoxic and hypoxic conditions. 
Conclusion: MRV infection induces downregulation of key proteins involved in tumor 
progression to androgen independent growth in hypoxic and normoxic androgen 
dependent LNCaP cells and also results in apoptosis induced cell death. As progression to 
androgen independence and tumor hypoxia are both well-characterized states associated 
with PCa progression, metastasis, and mortality, the evidence provided herein supports 
MRV as a viable potential therapeutic option for treatment of PCa at various stages of 
disease course. 
INTRODUCTION 
PCa is the second most common cancer causing death in men in the United States 
[1]. The growth and differentiation of prostate glands depends on androgens, testosterone 
and dihydrotestosterone (DHT). Growth-quiescent maintenance of the organ occurs in the 
presence of high levels of testosterone after puberty, but upon development, prostate 
tumors become dependent on androgen for growth. The androgen receptor (AR), a 
 127  
ligand-activated transcription factor, mediates androgen signaling in the cell making it a 
key protein in PCa progression [2]. Upon androgen binding, the AR translocates into the 
nucleus and, as a homodimer, binds to specific sequences (androgen response elements or 
ARE) in the regulatory elements of target genes promoting their transcription. AR-
dependent transcription requires the recruitment of coactivator proteins by AR, which 
increase the transcription rate and facilitate the growth of cancerous cells [3]. Thus 
androgen deprivation using either anti-androgens (such as bicalutamide), which directly 
inhibit the AR, or chemicals (such as Goserelin acetate sold as Zoladex from 
AstraZeneca) which block androgens, is an effective treatment for PCa. This treatment 
arrests the disease in the majority of cases, as evidenced by decrease in prostate specific 
antigen (PSA), a well-accepted marker for the diagnosis and prognosis of PCa, and a 
functional biomarker of AR activation [4]. However, relapse in the form of androgen-
independent PCa tumor growth occurs usually within 3 years following the onset of 
androgen deprivation. This androgen independent growth phase of PCa, also known as 
castration-resistant prostate cancer (CRPC), responds poorly to currently available 
treatments such as docetaxel and prednisone and is associated with metastasis and poor 
prognosis [5]. Establishing the AR as a valid therapeutic target for CRPC changed the 
focus of drug development towards AR targeting and drugs such as Enzalutamide 
(marketed as Xtandi by Medivation), which inhibits AR signaling were recently approved 
for treating CRPC [6]. 
Hypoxia is a condition of decreased oxygen levels that occurs within 
microenvironments of solid tumors, arising due to rapidly dividing tumor cells, which 
evade the blood supply. Hypoxic tumor cells are known to be resistant to chemotherapy 
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and radiation therapy and are strongly associated with disease progression and metastasis 
[7, 8]. In PCa, hypoxia has been found to influence disease progression, [9] increase gene 
instability, and inhibit apoptosis induction [10]. In PCa, hypoxia also leads to increased 
AR activity and sensitivity leading to PCa growth under very low androgen 
concentrations [11]. Relapsed CRPC strongly expresses hypoxia inducible factor 1α 
(HIF-1α), the master transcriptional regulator of the cellular hypoxic response, 
suggesting that castration-resistant tumor cells exist under hypoxic conditions [12]. The 
results of several studies suggest that HIF-1α works with AR to activate the expression of 
several genes related to tumor angiogenesis, invasion, and progression. Moreover, 
crosstalk between AR and HIF-1α has been described, and the PSA gene contains both 
an ARE and a HIF response element (HRE) [13]. Consequently hypoxia may facilitate 
disease progression through a synergistic effect of HIF-1 and AR to increase the 
expression of PSA, which itself has been reported to have a role in metastasis and 
migration [14]. In addition, hypoxia has been shown to influence androgen resistance and 
progression to CRPC [10]. A recent paper found that HIF-1α is likely to contribute to 
metastasis and chemo-resistance of CRPC and inhibition of HIF-1α may increase the 
responsiveness of CRPCs to chemotherapy [15]. Another feature shared by both 
androgen independent and hypoxic prostate tumors is the mutation or deletion of the 
tumor suppressor gene phosphatase and tensin homolog (PTEN) [16, 17]. PTEN inhibits 
the phosphoinositide 3-kinase/serine threonine protein kinase B (PI3K/AKT) pathway by 
dephosphorylating phosphoinositide-3,4,5 triphosphate (PIP3). PIP3 is responsible for 
recruiting Akt/PKB kinases to the cell membrane, driving their conformational changes 
and resulting in their phosphorylation by phosphoinositide-dependent kinase 1 (PDK1) 
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[18, 19]. The PI3K/Akt pathway in turn regulates the stimulation of cell cycle 
progression, survival, migration and metabolism. Thus, the loss of PTEN activity 
correlates with high Akt activity leading to apoptosis resistance and tumor growth in PCa 
[20-22]. Hypoxia and PI3K/Akt signaling have been reported to be both regulated, and 
induced by each other [17, 23-25]. Therefore it is clear that hypoxia and HIF-1α play a 
key role in various stages of prostate tumor growth and its progression from androgen-
sensitive to CRPC. 
Mammalian Orthoreovirus (MRV) is a clinically benign oncolytic virus that 
preferentially replicates in tumor cells over normal cells. Successful demonstration of 
MRV’s potent oncolytic activity in many different cancer types in animal models [26, 27] 
has resulted in testing the virus as a cancer therapy in a number of Phase I/II/III human 
clinical trials. These trials have proven MRV’s efficacy as a safe and applicable therapy 
for a number of cancer types where it leads to tumor regression or stabilization in many 
patients [28-34]. MRV has been shown to be effective against PCa cells in vitro, in an in 
vivo animal model and in human clinical trials [35-37]. Our lab recently demonstrated 
that MRV is successful in inducing apoptosis in androgen resistant (DU145, PC-3) PCa 
cells grown in normoxic and hypoxic conditions. Strikingly, we also showed that MRV 
induces a massive downregulation of HIF-1α in both androgen resistant and androgen 
sensitive (LNCaP) cells [38]. As multiple studies point towards a link between HIF-1α 
and AR regulation, we hypothesized that MRV infection may also impact AR regulation. 
Thus the objective of this study was to elucidate the effect of MRV and MRV-induced 
HIF-1α downregulation on the activity and protein levels of Akt, AR and PSA.  
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MATERIALS AND METHODS 
Cells and reagents LNCaP cells were maintained in RPMI media (ATCC), containing 
10% fetal bovine serum (Atlanta Biologicals) and penicillin-streptomycin (100 IU/ml, 
Mediatech). BHK-21 cells were maintained in DMEM (Sigma) containing 10% fetal 
bovine serum (Atlanta Biologicals), penicillin-streptomycin (100 IU/ml, Mediatech), L-
Glutamine (2nM, Mediatech) and 1% Non-Essential Amino acids (Invitrogen). Primary 
antibodies used were as follows: rabbit monoclonal anti-AR (catalog #5153), rabbit 
monoclonal anti-PSA (catalog #5365), rabbit monoclonal anti-Akt (catalog #4685), rabbit 
monoclonal anti-phospho-Akt (catalog #4060), rabbit polyclonal anti-FLAG (catalog 
#2368) (Cell Signaling Technologies), mouse monoclonal anti-HIF-1α (catalog 
#610958), mouse polyclonal anti-α-tubulin (catalog #T6074, Sigma) and rabbit 
polyclonal anti-µNS [39]. Secondary antibodies used for immunoblot experiments were 
alkaline phosphatase (AP)-conjugated goat anti-mouse (catalog #1706520) or anti-rabbit 
IgG (catalog #170-6518, Bio-Rad). Proteasome inhibitor, MG132 (Enzo Life Sciences), 
was used at a final concentration of 10 µM. 
Infection	  MRV	  virions	  (T3D	  strain)	  are	  from	  our	  laboratory	  stocks.	  Purified	  virions	  were	  prepared	  as	  described	  [40],	  using	  Vertrel	  reagent	  (DuPont)	  in	  place	  of	  Freon,	  and	  stored	   in	  dialysis	  buffer	   (150	  mM	  NaCl;	  10	  mM	  Tris	  pH	  7.4;	  10	  mM	  MgCl2)	  at	  4°C.	  Cells were seeded onto 60-mm, 35-mm, or 9.6-cm2 cell culture dishes 24 h before 
infection. Cells were infected with MRV virions at a cell	   infectious	   unit	   (CIU)	   of	   1	  based	  on	  titers	  determined	  on	  cell	  lines	  used	  as	  previously	  described	  [41].	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Hypoxia	  Hypoxic	  conditions	  were	  obtained	  by	  incubating	  cells	  in	  1%	  O2	  and	  5%	  CO2	  at	   37°C in a Galaxy 48R CO2 Incubator (New Brunswick Scientific) equipped with 1-
19% O2 controls. All cells were adapted to hypoxia for 4 h prior to infection. 
Immunoblotting Cells were lysed in 100 µL 2X SDS protein loading buffer (125 mM 
Tris HCl [pH 6.8], 200 mM DTT, 4% SDS, 0.2% Bromophenol blue, 20% Glycerol). 
Immunoblots were performed as previously described [41]. Blots were exposed to Lumi-
PhosTM WB Chemiluminescent Substrate (Thermo Scientific), and images were collected 
and quantified using a ChemiDoc XRS camera and QuantityOne software (Bio-Rad). All 
experiments were independently performed at least 3 times and representative results are 
shown. 
Plasmid Construction To create pARE-Luc, a firefly luciferase reporter plasmid 
(pGL4.26 luc2/minP/Hygro) was purchased from Promega. Upper and lower 
oligonucleotides were designed which contain three copies of the androgen response 
element, 5ʹ′ GTACGTGCT 3ʹ′, flanked on each end by NheI and HindIII restriction sites 
(New England Biolabs). Oligonucleotides were annealed and ligated into NheI and 
HindIII digested pGL4.26 luc2/minP/Hygro. To create FLAG-tagged AR and PSA 
expression plasmids, a gene specific forward primer containing the FLAG sequence 
flanked by an NheI restriction site and a gene specific reverse primer flanked by an XbaI 
restriction sites were used to amplify the AR and PSA genes using plasmids pEGFP-C1-
AR (Addgene plasmid 28235,	   [42]) and pCMV6-AC-PSA (SC324412, Origene) as 
templates. The resulting PCR product was digested and ligated into NheI/XbaI digested 
pCI-Neo. Following ligation, transformation, and screening, all plasmids were verified by 
sequencing.  
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Luciferase Assay Cells were transfected with pARE-luciferase using Lipofectamine 
2000 (Invitrogen) according to the supplier’s protocol. Luciferase expression was 
measured using the One-Glo Luciferase Assay Kit and the luminescence function of a 
GloMax Multi+ microplate reader (Promega). Following recording of luminescence, cells 
were lysed and total protein was measured using Bradford Assay (Biorad) and the 
absorbance function of a GloMax Multi+ microplate reader. Luminescence levels were 
normalized to total protein and plotted on a graph. Results shown are means and standard 
error of three experimental replicates. The statistical significance was calculated using the 
average of 3 experimental replicates. 
PSA ELISA ELISA test was performed using the Total PSA ELISA kit from DRG 
International, according to the manufacturer’s instruction. The color intensity (optical 
density) was measured using a GloMax Multi+ microplate reader and is directly 
proportional to the amount of antigen in the sample.  The cells were lysed and total 
protein measured using Bradford Assay (Biorad) and the absorbance function of a 
GloMax Multi+ microplate reader. PSA levels were normalized to total protein and 
plotted on a graph. Results shown are means and standard error of three experimental 
replicates, each with duplicate samples. 
Cell Viability and Caspase Activity Assay Cell viability assays were performed using 
the Cell-Titer Blue Viability Assay and Caspase activity was measured using Caspase 3/7 
Glo Assay from Promega, according to the manufacturer’s instruction. Fluorescence for 
the viability assay was measured using the GloMax Multi+ microplate reader and the 
values were plotted on a graph, with error bars depicting standard error. Following 
recording of luminescence for caspase assay, cells were lysed and total protein was 
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measured using Bradford Assay (Biorad). Luminescence levels were normalized to total 
protein and plotted on a graph. The experiments were performed independently thrice and 
each experiment had 3 replicates of each sample. 
Quantitative Real-Time PCR RNA was harvested using Trizol (Invitrogen) or Zyppy 
Direct-zol RNA miniprep kit as per manufacturer’s instruction. 100ng of RNA was 
subjected to qPCR using Power SYBR Green RNA-to-CT 1-step Kit from Applied 
Biosystems as per manufacture’s protocol. Primers used were as follows: β-actin (409 
bp): forward primer ACCAACTGGGACGACATGGAGAAA, reverse primer, 
TTAATGTCACGCACGATTTCCCGC; AR (168 bp): forward primer 
CCTGGCTTCCGCAACTTACAC, reverse primer GGACTTGTGCATGCGGTACTCA. 
β-actin CT values were used as a control and infected samples were normalized to 
uninfected samples in each condition. Fold differences were calculated using the PfaffI 
method. The experiment was done thrice independently and each experiment included 2 
sample replicates. The average of the three experiments was plotted on a bar graph with 
error bars depicting the standard error of the averages. 
Statistical Analysis Statistical significance was determined using student’s t-test and 
two-tailed p value calculated with GraphPad software. Differences in groups for which 
p<0.05 were considered to be statistically significant and are indicated with an asterisk in 
figures. 
RESULTS 
MRV infection induces apoptotic cell death in androgen dependent hypoxic prostate 
LNCaP tumor cells. MRV infection is known to induce apoptosis in cells growing under 
normoxic conditions, [43]  however, growth in hypoxic conditions leads to apoptosis 
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resistance via upregulation of anti-apoptotic factors [44-46] and downregulation of pro-
apoptotic factors [47]. We previously demonstrated that MRV infection induced 
apoptosis in androgen independent DU145 cells by activating both intrinsic and extrinsic  
 
 
Figure 5.1. MRV infection induces apoptotic cell death in androgen dependent 
normoxic and hypoxic LNCaP cells. LNCaP cells were mock infected or infected with 
MRV T3D and incubated in normoxic or hypoxic conditions. A) At 24 and 48 h p.i., cells 
were subjected to viability assays. B) At 24 and 48 hours, cells were lysed and caspase 
3/7 activity was measured and expressed relative to total protein. Error bars represent SE 
of three experimental replicates. Statistically significant differences (p<0.05) are marked 
with ‘*’.  
 
pathways [38]. To determine the impact of MRV infection on cell viability of androgen 
dependent LNCaP cells, we mock-infected or infected cells and allowed them to incubate 
for 12 or 24 h under either normoxic or hypoxic conditions. Cell viability was then 
measured using the Cell-Titer Blue viability assay.  In these experiments, MRV infection 
caused significantly reduced viability of normoxic LNCaP cells relative to uninfected 
cells, and further, MRV infection caused a similar reduction in viability of LNCaP cells 
grown under hypoxic conditions (Fig. 5.1A). To determine if cell death resulting from 
MRV infection was due to apoptosis, we repeated these experiments and measured 
caspase 3/7 activity. We found significantly increased caspase activity in both normoxic 
and hypoxic infected samples relative to uninfected samples (Fig. 5.1B), clearly showing 
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that MRV induces apoptosis and thus causes cell death in androgen sensitive LNCaP 
cells grown under both normoxic and hypoxic conditions. 
MRV infection induces downregulation of phosphorylated Akt. Akt, in its 
phosphorylated, active form (P-Akt), is a key regulator of protection of prostate tumor 
cells from apoptosis via inhibition of pro-apoptotic proteins such as Bax and BAD	   [22, 
48]. P-Akt also directly inhibits apoptosis via prevention of caspase 9 phosphorylation 
[49]. Akt activity is negatively regulated by PTEN dephosphorylation of PIP3, which is 
responsible for activation of Akt by inducing conformational changes and subsequent 
phosphorylation [18, 19]. In LNCaP cells, one allele of PTEN is deleted and the other is  
 
 
Figure 5.2. MRV induces decreased levels of Akt activity in normoxic and hypoxic 
LNCaP cells. LNCaP cells were mock infected or infected with MRV T3D and 
incubated under normoxic or hypoxic conditions. At 12 and 24 h p.i., cells were 
harvested and protein lysates were separated on SDS-PAGE and transferred to 
nitrocellulose. Blots were immunostained with rabbit α-phospho Akt, rabbit α-Akt (pan), 
rabbit α-µNS antiserum, or mouse α-α-tubulin antibodies followed by AP-conjugated 
goat α-rabbit or mouse secondary antibodies. To correct for loading differences between 
lanes, P-Akt and Akt bands were quantified and P-Akt levels relative to Akt were 
determined. Calculated levels of P-Akt in infected relative to uninfected cells are shown. 
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mutated, resulting in high Akt phosphorylation and apoptosis resistance [16, 21]. 
Hypoxia has also been linked to activating Akt and promoting cell survival [17, 23, 50]. 
Since we demonstrated that MRV induces apoptosis in LNCaP cells, we hypothesized 
that MRV infection in LNCaP cells may result in downregulation of p-Akt. To examine 
this possibility, LNCaP cells were mock infected or infected with MRV and incubated in 
normoxic or hypoxic conditions. At 12 and 24 h p.i., cells were lysed and proteins were 
separated on SDS-PAGE and immunoblotted with antibodies against Akt, phosphorylated 
Akt, and the MRV non-structural protein µNS. At both 12 and 24 h p.i., and in both 
normoxic and hypoxic conditions less P-Akt accumulated in infected cells relative to 
uninfected cells, while there were no substantial differences in total Akt protein levels in 
these cells (Fig. 5.2). These results suggest that MRV infection interferes with Akt 
phosphorylation and subsequent activity in androgen dependent LNCaP cells grown in 
both normoxic and hypoxic conditions, likely negatively impacting the apoptosis resistant 
phenotype conferred by PTEN deletion/mutation and hypoxia.  
MRV infection induces downregulation of AR protein and activity. Akt activity has 
been shown to upregulate AR protein levels [51]. As MRV infection resulted in 
decreased Akt phosphorylation, we reasoned that it might also impact AR protein levels 
in LNCaP cells. In addition, hypoxia has been found to cause increased AR activity by 
stimulating its nuclear translocation and increasing its ARE-binding activity [11]. Our 
previous findings that MRV downregulates the master transcriptional regulator of 
hypoxia, HIF-1α in LNCaP and other PCa cells [38] coupled with the downregulation of 
Akt phosphorylation demonstrated in Fig. 2, led us to hypothesize that MRV may 
negatively impact the AR. To test this we analyzed AR protein levels from lysates of 
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uninfected and infected LNCaP cells grown under hypoxic and normoxic conditions at 12 
h and 24 h p.i. by immunoblot analysis. In these experiments, there were substantially 
reduced levels of AR protein in both normoxic and hypoxic MRV infected LNCaP cells  
 
 
Figure 5.3. MRV induces downregulation of AR protein and activity in normoxic 
and hypoxic LNCaP cells. A) LNCaP cells were mock infected or infected with MRV 
T3D and incubated under normoxic or hypoxic conditions. At 12 and 24 h p.i., cells were 
harvested and proteins were separated on SDS-PAGE and transferred to nitrocellulose. 
Blots were immunostained with rabbit α-AR antibodies, rabbit α-µNS antiserum, or 
mouse α-α-tubulin antibodies followed by AP-conjugated goat α-rabbit or mouse 
secondary antibodies. To correct for loading differences between lanes, AR and α-tubulin 
bands were quantified and AR levels relative to α-tubulin were determined. Calculated 
levels of AR in infected relative to uninfected cells are shown. B) LNCaP cells were 
transfected with pARE-luc. 24 h post-transfection, cells were mock infected or infected 
with MRV T3D and incubated in normoxic or hypoxic conditions. At 24 or 48 h p.i., 
luciferase activity and total protein were measured. Relative amounts of luciferase per 
total protein are shown. Error bars represent SE of three independent experiments. 
Statistically significant differences (p<0.05) are marked with ‘*’. 
 
relative to uninfected cells (Fig. 5.3A). To extend this finding, we examined AR protein 
activity during MRV infection by measuring transcription from an AR dependent firefly 
luciferase plasmid (pARE-luc) transfected into mock- and MRV-infected LNCaP cells 
grown under normoxic and hypoxic conditions. Confirming our findings demonstrating 
decreased AR protein levels, these assays demonstrated a decrease in AR activity as 
measured by luciferase expression in infected cells relative to uninfected cells in both 
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normoxic and hypoxic conditions (Fig. 5.3B). Interestingly, we also observed an increase 
in AR activity in non-infected hypoxic LNCaP cells relative to non-infected normoxic 
LNCaP cells, a result that was not obvious in the immunoblot analysis of protein levels. 
Altogether, these results support the conclusion that MRV infection results in diminished 
levels of active AR protein in normoxic and hypoxic prostate tumor cells. 
AR downregulation in MRV infected cells occurs at the translational level. In the 
presence of hormone, AR protein levels are regulated by the ubiquitin/proteasome-
mediated degradation pathway [52, 53]. A putative PEST (proline, glutamate, serine and 
threonine rich) sequence present in the hinge-ligand binding domain of AR is proposed to 
be involved in its proteasomal degradation [52, 53].  In addition Akt and Mdm2 form a 
complex with AR, independent of the ligand, causing its phosphorylation and ubiquitin 
dependent proteasomal degradation [54]. In an effort to identify the step at which MRV 
impacts AR, we first examined AR protein accumulation in MRV infected cells in the 
presence of the proteasome inhibitor MG132. At 12 h p.i., uninfected and MRV-infected 
normoxic and hypoxic LNCaP cells were treated with MG132 for 12 h prior to harvesting 
and cell lysis. The lysate was separated on SDS-PAGE and immunoblotted using AR-
specific antibodies. HIF-1α, which we have previously demonstrated to be targeted to the 
proteasome during MRV infection, was included as a control to verify MG132 
proteasome inhibition. As shown in Fig. 5.4A, AR was not rescued from downregulation 
by MG132 in MRV infected cells indicating that, unlike HIF-1α, infection does not 
induce proteasome-dependent degradation of AR. To determine if MRV infection leads 
to decreased transcription of the AR gene, we performed qPCR assays on uninfected and 
infected LNCaP cells grown under normoxic and hypoxic conditions at 12 and 24 h p.i. 
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We found that under each condition, MRV infection led to significantly decreased levels 
of transcription of the AR gene relative to uninfected cells (Fig. 5.4B). Previous studies 




Figure 5.4. AR downregulation in MRV infected cells occurs at the translational 
level. A) LNCaP cells were mock infected or infected with MRV T3D and incubated 
under normoxic or hypoxic conditions. MG132 was added to cells at 12 h p.i. At 24 h 
p.i., cells were harvested and proteins separated on SDS-PAGE and transferred to 
nitrocellulose. Blots were immunostained with rabbit α-AR antibodies, rabbit α-µNS 
antiserum, mouse α-HIF-1α antibodies, or mouse α-α-tubulin antibodies followed by 
AP-conjugated goat α-rabbit or mouse secondary antibodies. B) LNCaP cells were mock 
infected or infected with MRV T3D and incubated under normoxic or hypoxic 
conditions. At 12 and 24 h p.i., total RNA was isolated and measured using qPCR. Data 
from three independent experiments are represented as mean ± standard error of the mean 
(SEM). Statistically significant differences (p<0.05) are marked with ‘*’. C) BHK-21 
cells were transfected with pFLAG-AR. 24 h post-transfection, cells were mock-infected 
or infected with MRV T3D and incubated in normoxic or hypoxic conditions. At 12 and 
24 h p.i., cells were harvested, proteins separated on SDS-PAGE and transferred to 
nitrocellulose. Blots were immunostained with rabbit α-FLAG antibodies, rabbit α-µNS 
antiserum, or mouse α-α-tubulin antibodies followed by AP-conjugated goat α-rabbit or 
mouse secondary antibodies. To correct for loading differences between lanes, FLAG and 
α-tubulin bands were quantified and FLAG levels relative to α-tubulin were determined. 
Calculated levels of FLAG in infected relative to uninfected cells are shown. D) BHK-21 
cells were transfected with pFLAG-AR. 24 h post-transfection, cells were mock infected 
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or infected with MRV T3D and incubated in normoxic or hypoxic conditions. MG132 
was added to cells at 8 h p.i. At 12 h and 24 h p.i., cells were harvested, proteins 
separated on SDS-PAGE and transferred to nitrocellulose. Blots were immunostained 
with rabbit α-FLAG antibodies, rabbit α-µNS antiserum, or mouse α-α-tubulin 
antibodies followed by AP-conjugated goat α-rabbit or mouse secondary antibodies.  
 
a subset of genes [55, 56] therefore it is possible that MRV induces a direct 
downregulation of AR transcription. However, because the AR gene contains an ARE in 
its promoter [57], and the AR protein upregulates transcription of the AR gene via 
binding to the ARE, another possibility is that the decrease in AR gene transcription 
measured in these experiments occurs indirectly as a result of MRV-induced 
downregulation of AR protein translation. It is well established that MRV infection 
induces a general downregulation of protein translation in a strain-dependent manner [58, 
59]. In order to test this possibility, we next examined AR protein levels in MRV-infected 
BHK cells transiently transfected with a plasmid expressing a FLAG tagged AR. Unlike 
the endogenous AR gene, the FLAG-tagged AR gene does not contain an ARE. Cell 
lysates were collected at 12 and 24 h p.i., and immunoblotted for FLAG and MRV non-
structural protein µNS.  In agreement with the results from MRV-infected LNCaP cells, 
the FLAG-AR protein was downregulated in the MRV infected BHK-21 cells relative to 
uninfected cells (Fig. 5.4C). Thus the expression of AR from a Flag-tagged AR plasmid 
that does not contain an ARE in its promoter is still diminished by MRV infection 
suggesting that the downregulation of AR protein in MRV infected cells occurs via 
inhibition of protein translation, and that this decrease in AR protein contributes to the 
loss of AR mRNA transcription measured in Fig. 4B. To confirm that FLAG tagged AR 
protein downregulation during MRV infection is independent of proteasome-mediated 
degradation, we examined FLAG-AR accumulation in infected cells in the presence of 
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MG132. BHK-21 cells transfected with the plasmid expressing FLAG-AR were mock 
infected or infected with MRV, and MG132 was added at 8 h p.i. Lysate was collected 
either at 12 or 24 h p.i., and immunostained with FLAG antibodies. Consistent with 
results from the endogenous AR protein, MG132 was unable to rescue the FLAG-AR in 
MRV infected cells (Fig. 5.4D), leading to the conclusion that MRV downregulates AR 
by inhibiting its translation, which subsequently results in AR mRNA transcription 
downregulation. 
MRV infection induces reduced PSA levels in normoxic and hypoxic cells. The 
expression of prostate specific antigen (PSA) is dependent on androgen signaling and has 
been used extensively as a marker of PCa growth. The binding of AR to AREs in the 
proximal promoter and a distal enhancer of the PSA gene, results in its transcription 
regulation	   [60, 61]. In addition, the PSA gene promoter region also contains a hypoxia 
response element (HRE), which is essential for HIF-1 binding in response to hypoxia 
[13]. HIF-1 interacts with AR on this region of the PSA gene to activate its expression 
under hypoxic conditions [13]. Since MRV infection causes downregulation of HIF-1α 
[38] and AR protein accumulation and activity (Fig. 5.3-5.4), we reasoned that PSA 
levels in MRV infected cells may also be impacted. To test this, LNCaP cells were 
infected with MRV or mock infected and incubated under hypoxic and normoxic 
conditions for 12 and 24 h p.i. Harvested cell lysates were then separated on SDS-PAGE 
and immunoblotted with anti-PSA antibodies. Similar to what was seen in AR 
experiments, PSA protein levels were reduced in MRV infected normoxic and hypoxic 
cells (Fig. 5.5A). Since PSA secreted in the serum is a direct measure for PCa diagnosis 
and monitoring, we also measured secreted PSA from uninfected and MRV infected 
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LNCaP cells growing under normoxic and hypoxic conditions using ELISA. In this 
assay, secreted PSA was also reduced in MRV infected, normoxic and hypoxic cells 
relative to uninfected cells confirming that MRV infection induces downregulation of  
 
 
Figure 5.5. MRV infection induces reduced PSA levels in normoxic and hypoxic 
cells. A) LNCaP cells were mock infected or infected with MRV T3D and incubated 
under normoxic or hypoxic conditions. At 12 and 24 h p.i., cells were harvested and 
proteins were separated on SDS-PAGE and transferred to nitrocellulose. Blots were 
immunostained with rabbit α-PSA antibodies, rabbit α-µNS antiserum, or mouse α-α-
tubulin antibodies followed by AP-conjugated goat α-rabbit or mouse secondary 
antibodies. To correct for loading differences between lanes, PSA and α-tubulin bands 
were quantified and PSA levels relative to α-tubulin were determined. Calculated levels 
of PSA in infected relative to uninfected cells are shown. B) LNCaP cells were mock 
infected or infected with MRV T3D and incubated under normoxic or hypoxic 
conditions. At 12 and 24 h p.i., media from the plates was collected and total PSA 
measured using ELISA, then cells were lysed and total protein was measured by Bradford 
assay. Relative amounts of PSA per total protein are shown. Error bars represent SE of 
three experimental replicates. Statistically significant differences (p<0.05) are marked 
with ‘*’. C) BHK-21 cells were transfected with pFLAG-AR. 24 h post-transfection, cells 
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were mock infected or infected with MRV T3D and incubated in normoxic or hypoxic 
conditions. At 12 and 24 h p.i., cells were harvested and proteins were separated on SDS-
PAGE and transferred to nitrocellulose. Blots were immunostained with rabbit α-FLAG 
antibodies, rabbit α-µNS antiserum, or mouse α-α-tubulin antibodies followed by AP-
conjugated goat α-rabbit or mouse secondary antibodies. To correct for loading 
differences between lanes, FLAG and α-tubulin bands were quantified and FLAG levels 
relative to α-tubulin were determined. Calculated levels of FLAG in infected relative to 
uninfected cells are shown. 
 
PSA (Fig. 5.5B). Interestingly, the downregulation of both the overall levels of total PSA 
protein, and the levels of secreted PSA was more drastic in MRV-infected hypoxic cells 
relative to MRV-infected normoxic cells, perhaps reflecting the downregulation of both 
AR and HIF-1α proteins during MRV infection under hypoxic conditions (this study and 
[38]). In order to determine if the decrease in PSA protein was solely the result of MRV-
induced AR/HIF-1α downregulation or whether MRV infection independently induced 
the downregulation of PSA, we created a FLAG tagged PSA expression construct, which 
does not contain either an ARE or HIF response element (HRE). BHK-21 cells were 
transfected with a plasmid expressing Flag-PSA, then mock infected or infected with 
MRV, and at 24 h p.i., cells were harvested and proteins were separated on SDS-PAGE 
and immunoblotted. Similar to endogenous PSA, MRV-infection was able to 
downregulate PSA; however, the downregulation was not as drastic as that seen with 
endogenous PSA in LNCaP cells (Fig. 5.5C). The reason for this difference is likely a 
result of the fact that endogenous PSA expression in MRV-infected cells is negatively 
influenced by MRV downregulation of AR (and in hypoxic cells, HIF-1α), whereas Flag-
tagged PSA expression, because of the absence of ARE (and HRE in hypoxic cells), is 
not influenced by the downregulation by MRV of either of these proteins. Altogether, 
these data suggest that MRV infection can induce downregulation of total PSA by 
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repressing AR and/or HIF-1α activity and also by AR independent protein 
downregulation. 
DISCUSSION 
 Most current first-line prostate tumor therapies are based on androgen 
deprivation. Although effective for an average of three years after treatment onset, the 
emergence of androgen independent CRPC is inevitable. At the CRPC disease stage, 
docetaxel with prednisone is the most common therapy option. For docetaxel-refractory 
metastatic CRPC, another line of treatment includes cabazitaxel or abiraterone in 
combination with prednisone [62].  A number of other drugs have also been approved by 
the Food and Drug Administration (FDA) for the treatment of CRPC, but despite this 
progress, it still remains a lethal disease with an estimated 30,000 deaths occurring in the 
USA in 2014 [1], and identification of alternative treatment options is critical. 
Prostate tumor cells appear to use Akt activity to stimulate growth independent of 
the AR when subjected to androgen independence [63]. We have found that MRV is able 
to downregulate P-Akt in cells that have not progressed to androgen independence, 
suggesting MRV may block the AR independent growth signal needed for prostate 
tumors to survive androgen ablation therapy. Moreover, Akt activity has also been 
associated with resistance to TRAIL induced apoptosis in LNCaP cells [64]. Akt 
activation also causes phosphorylation of pro-apoptotic protein BAD and thus inhibits 
apoptosis [48]. MRV induction of caspases and subsequent apoptosis in androgen 
dependent PCa cells in this and our prior study, whether or not it is mediated through 
downregulation of Akt activity, support the continued exploration of MRV as a critically 
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needed therapeutic for inducing cell death of androgen-dependent PCa and CRPC 
targeting androgen-independent pathways.  
 Androgen independent prostate tumors remain AR dependent [65] because they 
maintain functional AR signaling, even under very low androgen levels. Mechanisms 
behind maintenance of AR dependence post androgen independence include 1) the 
overexpression or gene amplification of the AR in the vast majority of CRPC [66-68], 
making even small amounts of hormone sufficient for growth, and 2) mutations in CRPC 
treated with anti-androgens, which may broaden ligand specificity [69, 70]. Additionally, 
studies have linked the AR with the emergence of androgen independent cells by 
demonstrating that ectopic expression of high levels of AR can transform androgen 
dependent cells to androgen independence [71]. Moreover, adapting LNCaP cells to low 
androgen levels induces increased AR mutations [72]. Thus therapies, such as MRV, 
which target the AR, when used in combination with current therapies may potentially 
have the capacity to delay or even stop progression to CRPC, although further research is 
needed to validate this claim. 
 Hypoxia increases the activity and sensitivity of AR [11] and consequently may 
trigger the selection of androgen independent phenotypes [71, 73]. Androgen ablation 
therapy has also been show to induce hypoxia in prostate tumor cells [12]. Because of the 
key role played by AR in the development of prostate tumors, and the link between 
hypoxia and PCa progression, it is important to identify therapies that target androgen 
dependent prostate tumor cells and AR under both normoxic and hypoxic conditions. In 
this study, we have shown that MRV may be one such therapy for prostate tumors during 
these stages of cancer progression by establishing that MRV can induce apoptosis of 
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androgen dependent LNCaP cells, downregulate AR protein and activity, and 
downregulate total cellular and secreted PSA levels under both normoxic and hypoxic 
conditions. 
We have previously shown that MRV induces apoptosis in androgen independent 
DU145 cells and induces downregulation of the master transcriptional activator of 
hypoxia, HIF-1α, in androgen dependent LNCaP cells and androgen independent DU145 
and PC3 cells. In this study we show that MRV infection also induces apoptosis and kills 
androgen sensitive cells. Thus MRV oncolytic therapy on prostate tumors may be a 
viable therapy at various stages of the disease and could be useful in delaying or even 
preventing progression to androgen independence. Perhaps more importantly, MRV is 
able to overcome the protective anti-apoptotic, cell proliferating characteristics induced 
by hypoxia and HIF regulated activities and therefore negate at least some of the effects 
of hypoxia on AR activity, thereby potentially preventing cancer growth and progression. 
We show here the capacity of MRV to not only kill prostate tumor cells, but also target 
the AR, which is key for prostate tumor survival, even after androgen ablation therapy is 
applied.  
MRV’s oncolytic properties have been tested in clinical trials and in in vivo 
mouse models for PCa [35, 37]. MRV induced reduction in tumor size in SCID/NOD 
mice following only a single intratumoral injection. In human patients, MRV also 
demonstrated antitumor activity by reducing tumor size with minimal side effects [35].  
MRV has also been shown to confer anti-PCa immunity by initiating a strong T-cell 
response towards the tumor cells [36]. Furthermore, MRV works in synergism in vitro 
and in animal studies with docetaxel, which is used widely for CRPC treatment [74], and 
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induces the downregulation of HIF-1α, an important driver of prostate tumor progression 
[38]. Our study, which shows that MRV infection modulates key proteins Akt and AR 
under conditions that drive prostate tumor progression, augments these studies and 
highlights another potential benefit of MRV treatment.  
CONCLUSIONS 
 In conclusion, in this study we have demonstrated that MRV infection in 
androgen dependent LNCaP cells leads to apoptosis and cell death under hypoxic and 
normoxic conditions, causes reduced Akt activity, reduced AR protein levels and activity, 
and reduced PSA protein levels. These findings extend the potential utility of MRV 
therapy for use at various stages of PCa disease progression, to 1) limit the harmful 
effects of hypoxia, which can be induced during androgen ablation therapy and lead to 
the development of androgen independent prostate tumor cells, 2) downregulate Akt 
activity which induces continued AR gain of function in spite of low androgen levels and, 
3) inhibit translation and thus downregulate AR protein and activity which is essential for 
continued growth and progression of both androgen dependent and independent PCa, 
evidenced by PSA levels which are also downregulated by MRV. 
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CHAPTER 6. GENERAL CONCLUSIONS 
  
 Oncolytic potential of MRV in many cancer types, including prostate, has already 
been established in numerous in vitro, in vivo and human clinical trials. However, there is 
little research on its effects on and ability to destroy hypoxic PCa cells. In this thesis, we 
aimed to describe and understand the consequences of MRV infection in PCa cells, at the 
molecular level.  
 We first investigated the ability of MRV to grow under hypoxic conditions in PCa 
cells. We used three human PCa cell lines (DU145, PC-3 and LNCaP) and found that 
MRV could translate mRNA and replicate in these hypoxic cells as efficiently as it does 
under normoxia. In addition, MRV infection also caused massive downregulation of the 
key hypoxia regulation protein HIF-1α and its activity. Analysis of HIF-1α mRNA by 
qPCR assay ruled out transcriptional regulation. By using MG132 to block the 
proteasome and translation labeling experiments, we established that this HIF-1α 
downregulation was ubiquitin dependent and proteasome mediated and also via 
translational inhibition. Moreover, the PAS domain on the HIF-1α gene and the presence 
of RACK1 protein was found to be required for MRV-induced downregulation of HIF-
1α. This study highlighted the probable therapeutic benefits of using MRV for treating 
hypoxic PCa cells and lays vital groundwork for the design of studies to test this in 
clinical trials.  
 We were curious to know whether MRV protein played a direct role in HIF-1α 
downregulation, we sought to answer it, by expressing individual MRV proteins with 
HIF-1α. Due to limited resources we were able to detect 5 of the 10 proteins by western 
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blot. Of all 10, (including the 5 we could not see on a blot), two proteins were able to 
induce HIF-1α downregulation. They were µ1, encoded by the M2 gene, and µ2, 
encoded by the M1 gene. We then further investigated and narrowed down regions of 
these proteins that are important for the downregulation of HIF-1α. We observed that 
there were strain specific differences in the extent of HIF-1α downregulation by the µ2 
protein, the T1L and T3DC caused more downregulation compared to T3DF. This 
difference was mapped down to the 208th amino acid, which is also responsible for 
causing morphological differences in the VFs. Although, the NTPase activity of µ2 was 
not required for HIF-1α downregulation, Deletion mutants of µ2 implicated the region 
containing aa 180-380 as necessary. Deletion mutants of µ1, based on the functional 
domains known, were used to distinguish the required domain for HIF-1α 
downregulation. This was narrowed down to the φ domain, which has been associated 
with apoptosis induction. The interesting findings from this work give way to further 
research about the pathways involved in the downregulation of HIF-1α by µ1 and µ2, 
and will help understand more about how MRV infection causes HIF-1α downregulation 
and potentially may also uncover previously unknown host-MRV interactions. 
 After we had established that MRV infection can overcome the inhibitory effects 
of the hypoxic microenvironment and also target HIF-1α, we investigated the pathways 
and proteins regulated by HIF-1α and hypoxia. They key of these, in reference to PCa, is 
the progression of androgen dependent cells to androgen independent phenotype, which 
has been extensively linked with hypoxia and HIF-1α presence. We tested our 
hypothesis, using androgen dependent human PCa cell line LNCaP. We found that MRV 
induced apoptosis in LNCaP cells and also inhibited Akt activity. In addition it caused 
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the downregulation of the AR protein, AR activity and also PSA secretion. Further, 
investigation into the mechanism of AR downregulation strongly pointed towards 
translational inhibition. This study highlighted the benefits of using MRV as an oncolytic 
agent at earlier stages in PCa, when the tumor is still androgen dependent. This lays 
important groundwork for future studies and clinical trials to analyze the synergistic 
effects of MRV infection with hormone therapy and investigate if MRV infection could 
slow down or inhibit the progression to androgen independence. 
 Overall, the results presented in this dissertation strengthen the evidence for 
MRV’s oncolytic success, especially in hypoxic PCa at both earlier and later stages of the 
disease. Thus, the data from this study should provide a fundamental evidence-based 
justification for clinicians towards the design of trials that comprise multi-modular 
therapy applying MRV to treat patients with tumors that contain hypoxic microregions. 
Future studies are needed to complexly understand the mechanism of MRV induced 
downregulation of HIF-1α, and if the proteins µ1 and µ2 are also the cause of this 
downregulation in infected hypoxic cells. In addition, the potential of MRV to either 
inhibit or slow down the progression of androgen dependent PCa to CRPC needs to be 
tested in a clinical setting.   
 
 	  
